<SEC-DOCUMENT>0001641172-25-002702.txt : 20250404
<SEC-HEADER>0001641172-25-002702.hdr.sgml : 20250404
<ACCEPTANCE-DATETIME>20250404103009
ACCESSION NUMBER:		0001641172-25-002702
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250401
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250404
DATE AS OF CHANGE:		20250404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AIM ImmunoTech Inc.
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-27072
		FILM NUMBER:		25812368

	BUSINESS ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801
		BUSINESS PHONE:		352-448-7797

	MAIL ADDRESS:	
		STREET 1:		2117 SW HIGHWAY 484
		CITY:			OCALA
		STATE:			FL
		ZIP:			32801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEMISPHERX BIOPHARMA INC
		DATE OF NAME CHANGE:	19950614
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:AIM="http://aimimmuno.com/20250401">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_AIM_aimimmuno.com_20250401 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20250401_20250401 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0000946644 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000004" name="dei:EntityCentralIndexKey">0000946644</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aim-20250401.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-04-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000946644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-01</xbrli:startDate>
        <xbrli:endDate>2025-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20250401__20250401_zEoRxmXvox6d"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 OR 15(d) of The</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported) <span id="xdx_905_edei--DocumentPeriodEndDate_c20250401__20250401_zlQyqmBdkhYc"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 1,
2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90D_edei--EntityRegistrantName_c20250401__20250401_z9cvOZbskze9"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000011" name="dei:EntityRegistrantName">AIM
IMMUNOTECH INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20250401__20250401_zRoyfAUQ98r3"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20250401__20250401_zBZQtpUsnMe1"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000013" name="dei:EntityFileNumber">001-27072</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20250401__20250401_zgX4MqKcIPFl"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000014" name="dei:EntityTaxIdentificationNumber">52-0845822</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(state
    or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20250401__20250401_ztIg4hpUU6p6"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000015" name="dei:EntityAddressAddressLine1">2117
    SW Highway 484</ix:nonNumeric></span>,</b></span><b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityAddressCityOrTown_c20250401__20250401_zUF4LcHRWrV2"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000016" name="dei:EntityAddressCityOrTown">Ocala</ix:nonNumeric>
    </span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250401__20250401_z9i6OmVgVl36"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000017" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20250401__20250401_zbRWP0HMRu8b"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000018" name="dei:EntityAddressPostalZipCode">34473</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span>(<b><span id="xdx_909_edei--CityAreaCode_c20250401__20250401_z63Hb83VKHPg"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000019" name="dei:CityAreaCode">352</ix:nonNumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span>
<span id="xdx_90A_edei--LocalPhoneNumber_c20250401__20250401_zW8Yf3SbExf6"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000020" name="dei:LocalPhoneNumber">448-7797</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--WrittenCommunications_c20250401__20250401_znMA30LaX94l"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--SolicitingMaterial_c20250401__20250401_zSVCUl06nqH4"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--PreCommencementTenderOffer_c20250401__20250401_zMvMBueM9Xta"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20250401__20250401_zMM5gVJlDTZe"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <b><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20250401__20250401_zDKoNlVjAeh3"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 27.8pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20250401__20250401_zZpK6kOeCOqf"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20250401__20250401_z9K83FpM0NRj"><ix:nonNumeric contextRef="AsOf2025-04-01" id="Fact000027" name="dei:TradingSymbol">AIM</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20250401__20250401_zAoAibW4NiCb"><ix:nonNumeric contextRef="AsOf2025-04-01" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE
    American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2025, AIM ImmunoTech Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;)
entered into an Equity Distribution Agreement (the &#8220;<span style="text-decoration: underline">Sales Agreement</span>&#8221;) with
Maxim Group LLC (&#8220;<span style="text-decoration: underline">Maxim</span>&#8221;), to sell shares of its common stock, par value
$0.001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;) for an aggregate offering price of
up to $3,000,000 of Common Stock (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) from time to time, through
an &#8220;at the market offering&#8221; program (the &#8220;<span style="text-decoration: underline">ATM Offering</span>&#8221;) under
which Maxim will act as an exclusive sales agent. At the current time, the Company can only sell
$663,329 due to the limitations of General Instruction I.B.6 of Form S-3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2025, the Company filed a universal shelf registration statement on Form S-3 (File No. 333286319) (the &#8220;<span style="text-decoration: underline">Registration
Statement</span>&#8221;) which includes a prospectus relating to the ATM Offering (the &#8220;<span style="text-decoration: underline">Prospectus</span>&#8221;) with the Securities
and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;). Once the SEC declares the Registration Statement effective, the Company will
be able to offer and sell Shares in the ATM Offering under the Prospectus through Maxim pursuant to the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of the Shares under the Sales Agreement may be made by any method that is deemed to be an &#8220;at the market&#8221; offering as defined
in Rule 415(a)(4) under the Securities Act of 1933, as amended (&#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), or by any other method permitted
by law. Maxim will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices. The compensation
payable to the Maxim for sales of Shares pursuant to the Sales Agreement will be 3.0% of the gross proceeds for any Shares sold to or
through Maxim. In addition, the Company has agreed to reimburse Maxim for certain expenses it incurs in the performance of its obligations
up to a maximum of $50,000, and $5,000 per quarter thereafter, under the Sales Agreement. The Sales Agreement may be terminated by the
Company or Maxim in accordance with the terms therein. The Company made certain customary representations, warranties and covenants concerning
the Company and the Shares in the Sales Agreement and agreed to indemnify Maxim against certain liabilities, including liabilities under
the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no obligation to sell any of the Shares, and may at any time suspend offers under the Sales Agreement. The ATM Offering will
terminate upon the earlier of (i) the sale of Shares under the Distribution Agreement having an aggregate offering price of $3 million,
24 months from the date of the Sales Agreement or the termination of the Sales Agreement by either the Company or Maxim upon the provision
of fifteen (15) days written notice. In addition, sales of Shares under the ATM Offering shall not exceed $3 million, unless and until
the Company files an amended or new Prospectus Supplement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company intends to use the net proceeds from the sale of Shares for working capital and general
corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement,
which is filed as an exhibit hereto and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
legal opinion of Silverman Shin &amp; Schneider PLLC relating to the Shares is filed as Exhibit 5.1 hereto and incorporated herein by
reference.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there
be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or other jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cautionary
Statement Regarding Forward-Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
current report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the &#8220;PSLRA&#8221;).
Words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;continue,&#8221;
&#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;upcoming&#8221; and other variations thereon and similar expressions (as well
as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of
these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider the various risk
factors and cautionary statements in its filings with the SEC. You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this current report. Among other things, for those statements, the Company claims the
protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of
these forward-looking statements to reflect events or circumstances that occur after the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following exhibits are filed herewith:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Equity Distribution Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Silverman Shin &amp; Schneider PLLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Silverman Shin &amp; Schneider PLLC (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SIGNATURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
    ImmunoTech Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 4,</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Thomas K. Equels</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels, CEO</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>


<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Omo1vfGupCSyCInodssxlnRHZre/R+ot25RoGBiGc75zhBiJnJa6QYbjvCxgj23XKIdQYo2M5ozeka3WKfhb4kVbx8q4/v2BGXkGPZOMo+Tkhd561xarFGQ8kdNJlEAo0ySG2UYEXz0jU+sKjdOqAWUq2DF1rNEpfg0Je/UkQ+2rrzogW00mhXAsB/kNkQwj2NJdPYivFooiE8Gon0DkTLfOuxZPh+ZLwqLB1tfZgf5v8AH/Hkp/ -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Exhibit
1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
ImmunoTech Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $3,000,000 Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Equity
Distribution Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
1, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300 Park Avenue, 16<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), proposes to issue and sell through Maxim Group LLC
(the &ldquo;<B><I>Agent</I></B>&rdquo;), as sales agent, shares of common stock, par value $0.001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;),
of the Company (the &ldquo;<B><I>Shares</I></B>&rdquo;) having an aggregate offering price of up to $3,000,000 on terms set forth
herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreement with the Agent (this &ldquo;<B><I>Agreement</I></B>&rdquo;) with respect to the sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><I>Representations and Warranties of the Company</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company represents and warrants to, and agrees with, the Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company has filed, or shall file, in accordance with the provisions of the Securities Act of 1933, as amended and the rules and regulations
thereunder (the &ldquo;<B><I>Rules and Regulations</I></B>&rdquo; and collectively with the Securities Act of 1933, the &ldquo;<B><I>Securities
Act</I></B>&rdquo;), with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;), a registration statement
on Form S-3, including a base prospectus, relating to certain securities including the Shares to be issued from time to time by the Company,
and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities
Exchange Act of 1934, as amended and the rules and regulations thereunder (the &ldquo;<B><I>Exchange Act</I></B>&rdquo;). The Company
has prepared a Prospectus Supplement to the Base Prospectus included as part of such registration statement specifically relating to
the Shares. The Company will furnish to the Agent, for use by the Agent, copies of the base prospectus included as part of such registration
statement, as supplemented by the Prospectus Supplement, relating to the Shares. Except where the context otherwise requires, &ldquo;<B><I>Registration
Statement</I></B>,&rdquo; as used herein, means the registration statement referred to herein, as amended at the time of such registration
statement&rsquo;s effectiveness for purposes of Section 11 of the Securities Act, as such section applies to the Agent, including (1)
all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (2) any information contained
or incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act, to the extent
such information is deemed, pursuant to Rule 430B or Rule 430C under the Securities Act, to be part of the registration statement at
such time, and (3) any registration statement filed to register the offer and sale of Shares pursuant to Rule 462(b) under the Securities
Act (the &ldquo;<B><I>462(b) Registration Statement</I></B>&rdquo;). Except where the context otherwise requires, &ldquo;<B><I>Base Prospectus</I></B>,&rdquo;
as used herein, means the base prospectus filed as part of the Registration Statement, together with any amendments or supplements thereto
as of the date of this Agreement. Except where the context otherwise requires, &ldquo;<B><I>Prospectus Supplement</I></B>,&rdquo; as
used herein, means the most recent prospectus relating to the Shares, filed or to be filed by the Company with the Commission as part
of the Base Prospectus pursuant to Rule 424(b) under the Securities Act and in accordance with the terms of this Agreement. Except where
the context otherwise requires, &ldquo;<B><I>Prospectus</I></B>,&rdquo; as used herein, means the Prospectus Supplement together with
the Base Prospectus attached to or used with the Prospectus Supplement, as may be amended or supplemented from time to time. &ldquo;<B><I>Permitted
Free Writing Prospectus</I></B>,&rdquo; as used herein, means the documents, if any, listed on <U>Schedule A</U> attached hereto and,
after the date hereof, any &ldquo;issuer free writing prospectus&rdquo; as defined in Rule 433 of the Securities Act, that is expressly
agreed to by the Company and the Agent in writing to be a Permitted Free Writing Prospectus. Any reference herein to the Registration
Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to
refer to and include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein pursuant to
Item 12 of Form S-3 (the &ldquo;<B><I>Incorporated Documents</I></B>&rdquo;), including, unless the context otherwise requires, the documents,
if any, filed as exhibits to such Incorporated Documents. For purposes of this Agreement, all references to the Registration Statement,
the Rule 462(b) Registration Statement, the Base Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B><I>EDGAR</I></B>&rdquo;).
All references in this Agreement to financial statements and schedules and other information which is &ldquo;described,&rdquo; &ldquo;contained,&rdquo;
&ldquo;included&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Prospectus or any Permitted Free
Writing Prospectus (or other references of like import) shall be deemed to mean and include all such financial statements and schedules
and other information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included
in the Registration Statement, the Base Prospectus, the Prospectus or Permitted Free Writing Prospectus as the case may be. Any reference
herein to the terms &ldquo;<B><I>amend</I></B>,&rdquo; &ldquo;<B><I>amendment</I></B>&rdquo; or &ldquo;<B><I>supplement</I></B>&rdquo;
with respect to the Registration Statement, any Base Prospectus, the Prospectus, the Prospectus Supplement or any Permitted Free Writing
Prospectus shall be deemed to refer to and include the filing of any document under the Securities Exchange Act of 1934, as amended,
and the rules and regulations thereunder (collectively, the &ldquo;<B><I>Exchange Act</I></B>&rdquo;) on or after the initial effective
date of the Registration Statement, or the date of such Base Prospectus, the Prospectus, the Prospectus Supplement or such Permitted
Free Writing Prospectus, if any, as the case may be, and incorporated or deemed to be incorporated therein by reference pursuant to Item
12 of Form S-3. &ldquo;<B><I>Time of Sale</I></B>&rdquo; means each time a Share is purchased pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
(A) The Registration Statement complies as of the date hereof, and will comply upon the effectiveness of the Registration Statement and
any amendment thereto and at each Time of Sale and each Settlement Date (as applicable), in all material respects, with the requirements
of the Securities Act; at all times during which a prospectus is required by the Securities Act to be delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule) in connection with any sale of Shares (the &ldquo;<B><I>Prospectus
Delivery Period</I></B>&rdquo;), the Registration Statement, as may be amended, will comply, in all material respects, with the requirements
of the Securities Act; the conditions to the use of Form S-3 in connection with the offering and sale of the Shares as contemplated hereby
(the &ldquo;<B><I>Offering</I></B>&rdquo;) have been satisfied, subject to the limitations required by General Instruction I.B.6 of Form
S-3; the Registration Statement meets, and the Offering complies with, the requirements of Rule 415 under the Securities Act (including,
without limitation, Rule 415(a)(5)); the Registration Statement did not, as of the date hereof, and will not, as of the effective date
of the Registration Statement or any amendment thereto, at each Time of Sale, if any, and at all times during a Prospectus Delivery Period,
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
The Prospectus, as of the date of the Prospectus Supplement, as of the date hereof (if filed with the Commission on or prior to the date
hereof), at each Settlement Date and Time of Sale (as applicable), and at all times during a Prospectus Delivery Period, complied, complies
or will comply, in all material respects, with the requirements of the Securities Act; and the Prospectus, and each supplement thereto,
as of their respective dates, at each Settlement Date or Time of Sale (as applicable), and at all times during a Prospectus Delivery
Period, did not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
Each Permitted Free Writing Prospectus, if any, as of its date and as of each Settlement Date and Time of Sale (as applicable), and at
all times during a Prospectus Delivery Period (when taken together with the Prospectus at such time) will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations and warranties set forth in subparagraphs (A), (B) and (C) above shall not apply to any statement contained in the Registration
Statement, the Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus in reliance upon and in conformity with information
concerning the Agent that is furnished in writing by or on behalf of the Agent expressly for use in the Registration Statement, the Base
Prospectus, the Prospectus or such Permitted Free Writing Prospectus, if any, it being understood and agreed that only such information
furnished by the Agent as of the date hereof consists of the information described in <U>Section 5(b)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any &ldquo;prospectus&rdquo;
(within the meaning of the Securities Act) or used any &ldquo;prospectus&rdquo; (within the meaning of the Securities Act) in connection
with the Offering, in each case other than the Base Prospectus or any Permitted Free Writing Prospectus; the Company has not, directly
or indirectly, prepared, used or referred to any Permitted Free Writing Prospectus except in compliance with Rules 164 and 433 under
the Securities Act; assuming that a Permitted Free Writing Prospectus, if any, is sent or given after the Registration Statement was
filed with the Commission (and after such Permitted Free Writing Prospectus, if any, was, if required pursuant to Rule 433(d) under the
Securities Act, filed with the Commission), the Company will satisfy the provisions of Rule 164 or Rule 433 necessary for the use of
a free writing prospectus (as defined in Rule 405) in connection with the Offering; the conditions set forth in one or more of subclauses
(i) through (iv), inclusive, of Rule 433(b)(1) under the Securities Act are satisfied, and the Registration Statement relating to the
Offering, as initially filed with the Commission, includes a prospectus that, other than by reason of Rule 433 or Rule 431 under the
Securities Act, satisfies the requirements of Section 10 of the Securities Act; neither the Company nor the Agent is disqualified, by
reason of subsection (f) or (g) of Rule 164 under the Securities Act, from using, in connection with the Offering, &ldquo;free writing
prospectuses&rdquo; (as defined in Rule 405 under the Securities Act) pursuant to Rules 164 and 433 under the Securities Act; the Company
is not an &ldquo;ineligible issuer&rdquo; (as defined in Rule 405 under the Securities Act) as of the eligibility determination date
for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares contemplated by the Registration
Statement; the parties hereto agree and understand that the content of any and all &ldquo;road shows&rdquo; (as defined in Rule 433 under
the Securities Act) related to the Offering is solely the property of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Each Permitted Free Writing Prospectus, as of its issue date, each Time of Sale and each Settlement Date occurring after such issue date
and at all subsequent times through the Prospectus Delivery Period (as defined below) or until any earlier date that the Company notified
or notifies the Agent as described in <U>Section 3(c)(iii)</U>, did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement, any Base Prospectus or the Prospectus. The foregoing
sentence does not apply to statements in or omissions from any Permitted Free Writing Prospectus based upon and in conformity with written
information furnished to the Company by the Agent specifically for use therein, it being understood and agreed that the only such information
furnished by the Agent as of the date hereof consists of the information described in <U>Section 5(b) (ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The financial statements, including the notes thereto, and the supporting schedules incorporated by reference in the Registration Statement
and the Prospectus comply in all material respects with the requirements of the Securities Act, the Exchange Act and the Rules and Regulations,
and present fairly the financial condition of the Company and its subsidiaries (as identified in the Registration Statement and Prospectus,
the &ldquo;<B><I>Subsidiaries</I></B>&rdquo;) and financial position as of the dates indicated and the cash flows and results of operations
for the periods specified of the Company. Except as otherwise stated in the Registration Statement and the Prospectus, said financial
statements have been prepared in conformity with United States generally accepted accounting principles (&ldquo;<B><I>GAAP</I></B>&rdquo;)
applied on a consistent basis throughout the periods involved. Any selected financial data and summary financial information included
in the documents in the Registration Statement and in the Prospectus constitute or will constitute a fair summary of the information
purported to be summarized and have been compiled on a basis consistent with that of the audited financial statements included in the
Registration Statement. No other financial statements or supporting schedules are required to be included or incorporated by reference
in the Registration Statement or the Prospectus. All disclosures, if any, contained in the Registration Statement or the Prospectus or
incorporated by reference therein regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the applicable rules
and regulations of the Commission) comply, in all material respects, with Regulation G of the Exchange Act and Item 10 of Regulation
S-K of the Securities Act to the extent applicable. The other financial information included in the Registration Statement and the Prospectus
present fairly the information included therein and have been prepared on a basis consistent with that of the financial statements that
are included in the Registration Statement and the Prospectus and the books and records of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The Company and each of its Subsidiaries has been duly incorporated and validly exists as a corporation in good standing under the laws
of its jurisdiction of incorporation. The Company and each of its Subsidiaries has all requisite corporate power and authority to own,
lease and operate its respective properties and carry on its business as it is currently being conducted and as described in the Registration
Statement and the Prospectus. The Company and each of its Subsidiaries is duly qualified to do business and is in good standing as a
foreign corporation in each jurisdiction in which the character or location of its properties (owned, leased or licensed) or the nature
or conduct of its business makes such qualification necessary, except, in each case, for those failures to be so qualified or in good
standing which (individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
All of the issued shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable,
have been issued in compliance in all material respects with all applicable federal and state securities laws and none of those shares
was issued in violation of any preemptive rights, rights of first refusal or other similar rights to the extent any such rights were
not waived; the Shares have been duly authorized and, when issued and delivered against payment therefor as provided in this Agreement,
will be validly issued, fully paid and non-assessable, and the issuance of the Shares is not subject to any preemptive rights, rights
of first refusal or other similar rights that have not heretofore been waived (with copies of such waivers provided or made available
to the Agent). The Shares conform in all material respects to the descriptions thereof contained in the Registration Statement and the
Prospectus under the heading &ldquo;Description of Capital Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
BDO USA, P.C. (the &ldquo;<B><I>Auditor</I></B>&rdquo;), whose reports relating to the Company are incorporated by reference into
the Registration Statement and the Prospectus, is an independent registered public accounting firm as required by the Securities Act,
the Exchange Act and the Rules and Regulations and the Public Company Accounting Oversight Board (the &ldquo;<B><I>PCAOB</I></B>&rdquo;).
To the Company&rsquo;s knowledge, the Auditor is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act
of 2002 (&ldquo;<B><I>Sarbanes-Oxley</I></B>&rdquo;) as such requirements pertain to the Auditor&rsquo;s relationship with the Company.
Except as disclosed in the Registration Statement and the Prospectus, and except for any such non-audit services that were pre-approved
by the Audit Committee of the Company&rsquo;s Board of Directors in accordance with Sections 10A(h) and (i) of the Exchange Act, the
Auditor has not, during the periods covered by the financial statements included in the Registration Statement and the Prospectus, provided
to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Subsequent to the respective dates as of which information is presented in the Registration Statement and the Prospectus, and except
as disclosed in the Registration Statement and the Prospectus: (i) the Company (including its Subsidiaries) has not declared, paid or
made any dividends or other distributions of any kind on or in respect of its capital stock, and (ii) there has been no material adverse
change or, to the Company&rsquo;s knowledge, any development which could reasonably be expected to result in a material adverse change,
whether or not arising from transactions in the ordinary course of business, in or affecting: (A) the business, condition (financial
or otherwise), results of operations, stockholders&rsquo; equity, properties or prospects of the Company and its Subsidiaries taken as
a whole; (B) the long-term debt or capital stock of the Company and its Subsidiaries taken as a whole; or (C) the Offering or consummation
of any of the other transactions contemplated by this Agreement, the Registration Statement and the Prospectus (a &ldquo;<B><I>Material
Adverse Effect</I></B>&rdquo;). Since the date of the latest balance sheet included in the Registration Statement and the Prospectus,
the Company (including its Subsidiaries) has not incurred or undertaken any liabilities or obligations, whether direct or indirect, liquidated
or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business or asset,
which are material to the Company and its Subsidiaries taken as a whole, except (I) for liabilities, obligations and transactions which
are disclosed in the Registration Statement and the Prospectus and (II) as would not be reasonably expected (individually or in the aggregate)
to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
There are no statutes, regulations, contracts or documents that are required to be described in the Registration Statement and the Prospectus
or to be filed as exhibits to the Registration Statement by the Securities Act that have not been so described or filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
Neither the Company nor any of its Subsidiaries is: (i) in violation of its certificate of incorporation or bylaws or other organizational
documents, (ii) in default under any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it
is a party or by which it is bound or to which any of its property or assets is subject; and no event has occurred which, with notice
or lapse of time or both, would constitute a default under or result in the creation or imposition of any lien, security interest, charge
or other encumbrance (a &ldquo;<B><I>Lien</I></B>&rdquo;) upon any of its property or assets pursuant to, any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property
or assets is subject, or (iii) in violation in any respect of any applicable law, rule, regulation, ordinance, directive, judgment, decree
or order of any judicial, regulatory or other legal or governmental agency or body, foreign or domestic, except, in the case of subsections
(ii) and (iii) above, for such violations, defaults or Liens which (individually or in the aggregate) would not reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
The Company has all requisite corporate power and authority to execute and deliver this Agreement and all other agreements, documents,
certificates and instruments required to be delivered pursuant to this Agreement. The Company&rsquo;s execution, delivery and performance
under this Agreement and each of the transactions contemplated hereby have been duly authorized by all necessary corporate action. This
Agreement has been duly and validly executed and delivered by the Company and constitutes the legal, valid and binding obligation of
the Company and is enforceable against the Company in accordance with its terms, except (i) as such enforceability may be limited by
bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification
or contribution provision may be limited under federal and state securities laws; and (iii) that the remedy of specific performance and
injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which
any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
The execution, delivery and performance of this Agreement and all other agreements, documents, certificates and instruments required
to be delivered pursuant to this Agreement and the consummation of the transactions contemplated hereby do not and will not: (i) conflict
with, require consent under or result in a breach of any of the terms and provisions of, or constitute a default (or an event which with
notice or lapse of time, or both, would constitute a default) under, or result in the creation or imposition of any Lien upon any property
or assets of the Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement, instrument, franchise,
license or permit to which the Company is a party or by which the Company or any of its properties, operations or assets may be bound,
(ii) violate or conflict with any provision of the certificate of incorporation, bylaws or other organizational documents of the Company,
(iii) violate or conflict with any applicable law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial,
regulatory or other legal or governmental agency or body, domestic or foreign, or (iv) trigger a reset or repricing of any outstanding
securities of the Company, except in the case of subsections (i) and (iii) for any default, conflict, violation or Lien that would not
reasonably be expected to result in a Material Adverse Effect and except in the case of subsection (iv) for any trigger for which the
Company has received a waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
Except as disclosed in the Registration Statement and the Prospectus, the Company and each of its Subsidiaries has all consents, approvals,
authorizations, orders, registrations, qualifications, licenses, filings, grants, certificates and permits of, with and from all judicial,
regulatory and other legal or governmental agencies, self-regulatory agencies, authorities and bodies and all third parties, foreign
and domestic, including, without limitation, the U.S. Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;) or equivalent in
non-U.S. jurisdictions (collectively, the &ldquo;<B><I>Consents</I></B>&rdquo;), to own, lease and operate its properties and conduct
its business as it is now being conducted and as disclosed in the Registration Statement and the Prospectus, and each such Consent is
valid and in full force and effect, except which (individually or in the aggregate), in each such case, would not reasonably be expected
to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received notice of any investigation or proceedings
which results in or, if decided adversely to the Company or such Subsidiary, could reasonably be expected to result in, the revocation
of, or imposition of a restriction on, any Consent, except such restriction or revocation of such Consent which (individually or in the
aggregate) would not reasonably be expected to have a Material Adverse Effect. No Consent contains any material restriction not adequately
disclosed in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
The Company and each of its Subsidiaries is in compliance with all applicable laws, rules, regulations, ordinances, directives, judgments,
decrees and orders, foreign and domestic, except for any non-compliance the consequences of which would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
Prior to the Settlement Date, the Shares shall have been approved for listing on the NYSE American, subject to official notice of issuance
(the &ldquo;<B><I>Exchange</I></B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect of, delisting
the Shares nor, except as disclosed in the Registration Statement and the Prospectus, has the Company received any notification that
the Exchange is contemplating terminating such listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)
No consents, approvals, authorizations, orders, registrations, qualifications, licenses, filings grants certifications and permits of,
with or from any judicial, regulatory or other legal or governmental agency or body or any third party, foreign or domestic is required
for the execution, delivery and performance of this Agreement or consummation of each of the transactions contemplated by this Agreement,
including the issuance, sale and delivery of the Shares to be issued, sold and delivered hereunder, except (i) such as may have previously
been obtained (with copies of such consents provided to the Agent), each of which is in full force and effect as of the date hereof,
(ii) the registration under the Securities Act of the Shares, which has become effective and which remains in full force and effect as
of the date hereof and (iii) such consents as may be required under state securities or blue sky laws or the bylaws and rules of the
Exchange. The Base Prospectus has been filed with the Financial Industry Regulatory Authority, Inc. (&ldquo;<B><I>FINRA</I></B>&rdquo;)
and the required filing fee has been paid to FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)
Except as disclosed in the Registration Statement and the Prospectus, there is no judicial, regulatory, arbitral or other legal or governmental
proceeding or other litigation or arbitration, domestic or foreign, pending to which the Company or any of its Subsidiaries is a party
or of which any property, operations or assets of the Company or its Subsidiaries is the subject which (i) individually or in the aggregate,
if determined adversely to the Company or applicable Subsidiary would reasonably be expected to have a Material Adverse Effect, or (ii)
is reasonably likely to materially and adversely affect the consummation of the transactions contemplated in this Agreement or the performance
by the Company of its obligations hereunder. To the Company&rsquo;s knowledge, no such proceeding, litigation or arbitration is threatened
or contemplated against the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)
The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived
from sources which the Company reasonably and in good faith believes are reliable and accurate, and the Company has obtained the written
consent to the use of such data from such sources, to the extent required, except for such failures to obtain written consent which (individually
or in the aggregate) would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
The Company has established and maintains disclosure controls and procedures over financial reporting (as defined in Rules 13a-15 and
15d-15 under the Exchange Act) and such controls and procedures are designed to ensure that information relating to the Company required
to be disclosed in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s
management, including its principal executive and principal financial officer, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure. The Company has utilized such controls and procedures in preparing and evaluating
the disclosures in the Registration Statement and in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi)
Except as disclosed in the Registration Statement and the Prospectus, neither the board of directors nor the audit committee has been
informed, nor is the Company aware, of: (i) any significant deficiencies or material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize
and report financial information; or (ii) any fraud, whether or not material, that involves management or other employees who have a
significant role in the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii)
The Company has not taken, directly or indirectly, any action which constitutes or is designed to cause or result in, or which could
reasonably be expected to constitute, cause or result in, the stabilization or manipulation of the price of any security to facilitate
the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii)
Neither the Company nor any of its Affiliates (within the meaning of the Securities Act) has, prior to the date hereof, made any offer
or sale of any securities which are required to be &ldquo;integrated&rdquo; pursuant to the Securities Act or the Rules and Regulations
with the offer and sale of the Shares pursuant to the Registration Statement. Except as disclosed in the Registration Statement and the
Prospectus or Forms 4 filed by Affiliates, neither the Company nor any of its Affiliates has sold or issued any securities during the
six-month period preceding the date of the Prospectus, including but not limited to any sales pursuant to Rule 144A, Regulation D or
Regulation S under the Securities Act, other than shares of Common Stock issued pursuant to equity incentive plans, employee stock purchase
plans, employee benefit plans, qualified stock option plans or employee compensation plans or pursuant to outstanding options, convertible
notes, convertible preferred stock, rights or warrants to purchase shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv)
To the knowledge of the Company, the biographies of the Company&rsquo;s officers and directors incorporated into the Registration Statement
are true and correct in all material respects and the Company has not become aware of any information which would cause the information
disclosed in the questionnaires previously completed by the directors and officers of the Company to become inaccurate and incorrect
in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv)
To the knowledge of the Company, no director or officer of the Company is subject to any non-competition agreement or non-solicitation
agreement with any employer or prior employer which could materially affect his or her ability to be and act in his or her respective
capacity of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvi)
The Company is not and, at all times up to and including the consummation of the transactions contemplated by this Agreement, and after
giving effect to application of the Net Proceeds (as defined below), will not be, subject to registration as an &ldquo;investment company&rdquo;
under the Investment Company Act of 1940, as amended, and is not and will not be an entity &ldquo;controlled&rdquo; by an &ldquo;investment
company&rdquo; within the meaning of such act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvii)
No relationship, direct or indirect, exists between or among any of the Company or, to the Company&rsquo;s knowledge, any Affiliate of
the Company, on the one hand, and any director, officer, stockholder, customer or supplier of the Company or, to the Company&rsquo;s
knowledge, any Affiliate of the Company, on the other hand, which is required by the Securities Act, the Exchange Act or the Rules and
Regulations to be described in the Registration Statement or the Prospectus which is not so described as required. There are no outstanding
loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the
Company to or for the benefit of any of the officers or directors of the Company or any of their respective family members, except as
described in the Registration Statement and the Prospectus. The Company has not, in violation of Sarbanes-Oxley, directly or indirectly
extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a personal loan
to or for any director or executive officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxviii)
Except as disclosed in the Registration Statement and the Prospectus, the Company is in compliance with the rules and regulations promulgated
by the Exchange or any other governmental or self-regulatory entity or agency having jurisdiction over the Company, except for such failures
to be in compliance which (individually or in the aggregate) would not reasonably be expected to have a Material Adverse Effect. Without
limiting the generality of the foregoing: (i) all members of the Company&rsquo;s board of directors who are required to be &ldquo;independent&rdquo;
(as that term is defined under the rules of the Exchange), including, without limitation, all members of the audit committee of the Company&rsquo;s
board of directors, meet the qualifications of independence as set forth under applicable laws, rules and regulations and (ii) the audit
committee of the Company&rsquo;s board of directors has at least one member who is an &ldquo;audit committee financial expert&rdquo;
(as that term is defined under applicable laws, rules and regulations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxix)
The Company and each of its Subsidiaries owns or leases all such properties (other than intellectual property, which is covered below)
as are necessary to the conduct of its business as presently operated and as described in the Registration Statement and the Prospectus.
The Company and each of its Subsidiaries has good and marketable title in fee simple to all real property and good and marketable title
to all personal property owned by it, in each case free and clear of all Liens except such as are described in the Registration Statement
and the Prospectus or such as would not (individually or in the aggregate) have a Material Adverse Effect. Any real property and buildings
held under lease or sublease by the Company or its Subsidiaries are held by it under valid, subsisting and, to the Company&rsquo;s knowledge,
enforceable leases with such exceptions as are not material to, and do not materially interfere with, the use made and proposed to be
made of such property and buildings by the Company or its Subsidiaries. Neither the Company nor its Subsidiaries has received any written
notice of any claim adverse to its ownership of any real or material personal property or of any claim against the continued possession
of any real property, whether owned or held under lease or sublease by the Company or its Subsidiaries, except for such claims that,
if successfully asserted against the Company or its Subsidiaries, would not (individually or in the aggregate) reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxx)
The Company (including all of its Subsidiaries): (i) owns, possesses or has the right to use all patents, patent applications, trademarks,
service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, customer lists and know-how and
other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures, &ldquo;<B><I>Intellectual Property</I></B>&rdquo;) necessary for the conduct of its businesses as being conducted
and as described in the Registration Statement and the Prospectus, except as disclosed in the Registration Statement or the Prospectus,
and (ii) has no knowledge that the conduct of its business conflicts or will conflict with the rights of others, and it has not received
any written notice of any claim of conflict with, any right of others. To the Company&rsquo;s knowledge, there is no infringement by
third parties of any such Intellectual Property. There is no pending or, to the Company&rsquo;s knowledge, threatened, action, suit,
proceeding or claim by others challenging the Company&rsquo;s rights in or to any such Intellectual Property, and the Company is unaware
of any facts which would form a reasonable basis for any such claim; and there is no pending or, to the Company&rsquo;s knowledge, threatened,
action, suit, proceeding or claim by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade
secret or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any
such claim. Except as set forth in the Registration Statement and the Prospectus, the Company has not received any claim for royalties
or other compensation from any person, including any employee of the Company who made inventive contributions to Company&rsquo;s technology
or products that are pending or unsettled, and except as set forth in the Registration Statement and the Prospectus the Company does
not and will not have any obligation to pay royalties or other compensation to any person on account of inventive contributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxi)
The agreements and documents described in the Registration Statement and the Prospectus conform in all material respects to the descriptions
thereof contained therein and there are no agreements or other documents required by the applicable provisions of the Securities Act
to be described in the Registration Statement or the Prospectus or to be filed with the Commission as exhibits to the Registration Statement,
that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company
(or its Subsidiaries) is a party or by which its property or business is or may be bound or affected and (i) that is referred to in the
Registration Statement or the Prospectus or attached as an exhibit thereto, or (ii) is material to the Company&rsquo;s business, has
been duly and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company
in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws
affecting creditors&rsquo; rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under
the foreign, federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable
relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought,
and none of such agreements or instruments has been assigned by the Company (including any Subsidiaries), and neither the Company nor,
to the Company&rsquo;s knowledge, any other party is in material breach or default thereunder and, to the Company&rsquo;s knowledge,
no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a breach or default thereunder,
in any such case, which would result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxii)
The disclosures in the Registration Statement and the Prospectus concerning the effects of foreign, federal, state and local regulation
on the Company&rsquo;s business as currently contemplated are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiii)
The Company has accurately prepared and filed all federal, state, foreign and other tax returns that are required to be filed by it through
the date hereof, or has received timely extensions thereof, except where the failure to so file would not (individually or in the aggregate)
reasonably be expected to have a Material Adverse Effect, and has paid or made provision for the payment of all material taxes, assessments,
governmental or other similar charges, including without limitation, all sales and use taxes and all taxes which the Company is obligated
to withhold from amounts owing to employees, creditors and third parties, with respect to the periods covered by such tax returns, whether
or not such amounts are shown as due on any tax return (except as currently being contested in good faith and for which reserves required
by GAAP have been created in the financial statements of the Company) and except for such taxes, assessments, governmental or other similar
charges the nonpayment of which would not (individually or in the aggregate) reasonably be expected to have a Material Adverse Effect.
No deficiency assessment with respect to a proposed adjustment of the Company&rsquo;s federal, state, local or foreign taxes is pending
or, to the Company&rsquo;s knowledge, threatened. The accruals and reserves on the books and records of the Company in respect of tax
liabilities for any taxable period not finally determined are adequate to meet any assessments and related liabilities for any such period
and, since the date of the Company&rsquo;s most recent audited financial statements, the Company has not incurred any material liability
for taxes other than in the ordinary course of its business. There is no tax lien, whether imposed by any federal, state, foreign or
other taxing authority, outstanding against the assets, properties or business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiv)
No labor disturbance or dispute by or with the employees of the Company which, individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect, currently exists or, to the Company&rsquo;s knowledge, is threatened. The Company is in compliance
in all material respects with the labor and employment laws and collective bargaining agreements and extension orders applicable to its
employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxv)
Except as would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect, the Company (and its
Subsidiaries) is in compliance with all material Environmental Laws (as hereinafter defined), and, to the Company&rsquo;s knowledge,
no future material expenditures are or will be required in order to comply therewith. The Company has not received any written notice
or communication that relates to or alleges any actual or potential violation or failure to comply with any Environmental Laws that would,
individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. As used herein, the term &ldquo;<B><I>Environmental
Laws</I></B>&rdquo; means all applicable laws and regulations, including any licensing, permits or reporting requirements, and any action
by a federal, state or local government entity, pertaining to the protection of the environment, protection of public health, protection
of worker health and safety, or the handling of hazardous materials, including without limitation, the Clean Air Act, 42 U.S.C. &sect;
7401, et seq., the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. &sect; 9601, et seq., the
Federal Water Pollution Control Act, 33 U.S.C. &sect; 1321, et seq., the Hazardous Materials Transportation Act, 49 U.S.C. &sect; 1801,
et seq., the Resource Conservation and Recovery Act, 42 U.S.C. &sect; 690-1, et seq., and the Toxic Substances Control Act, 15 U.S.C.
&sect; 2601, et seq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvi)
As to each product or product candidate subject to the jurisdiction of the FDA under the Federal Food, Drug and Cosmetic Act, as amended,
and the regulations thereunder (&ldquo;<B><I>FDCA</I></B>&rdquo;) and/or the jurisdiction of the non-U.S. counterparts thereof that is
currently being tested by the Company (or any of its Subsidiaries) (each such product, a &ldquo;<B><I>Product</I></B>&rdquo;), such Product
is being tested by the Company in compliance with all applicable requirements under FDCA and/or and similar laws, rules and regulations
relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices,
good laboratory practices, good clinical practices, product listing, quotas, advertising, record keeping and filing of reports, except
where the failure to be in compliance would not have a Material Adverse Effect. Except as disclosed in the Registration Statement and
the Prospectus, the Company currently has no products that have been approved by the FDA or any non-U.S. counterparts thereof to be manufactured,
packaged, labeled, distributed, sold and/or marketed. Except as disclosed in the Registration Statement or the Prospectus, there is no
pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative
or regulatory proceeding, charge, complaint, or investigation) against the Company and the Company has not received any written notice,
warning letter or other communication from the FDA or any other governmental entity or any non-U.S. counterparts thereof, in either case
which (i) contests the premarket clearance, licensure, registration or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any Product, (ii) imposes a clinical hold on any clinical
investigation by the Company, (iii) enters or proposes to enter into a consent decree of permanent injunction with the Company, or (iv)
otherwise alleges any violation of any laws, rules or regulations by the Company, and which, either individually or in the aggregate,
would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all
material respects in accordance with all applicable laws, rules and regulations of the FDA and non-U.S. counterparts thereof. The Company
has not been informed by the FDA or any non-U.S. counterparts thereof that such agency will prohibit the marketing, sale, license or
use of any Product nor has the FDA or a non-U.S. counterpart thereof provided any written notice that could reasonably be expected to
preclude the approval or the clearing for marketing of any Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvii)
The clinical, pre-clinical and other studies and tests (&ldquo;<B><I>Studies</I></B>&rdquo;) conducted by or on behalf of or sponsored
by the Company (including its Subsidiaries) that are described or referred to in the Registration Statement and the Prospectus were and,
if still pending, are, being conducted in accordance with all applicable statutes, laws, rules and regulations (including, without limitation,
those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar
to those performed by the FDA), as well as the protocols, procedures and controls designed and approved for such Studies and with standard
medical and scientific research procedures, except where the failure to be so conducted would not have a Material Adverse Effect. The
descriptions of the results of such Studies that are described or referred to in the Registration Statement and the Prospectus are accurate
and complete in all material respects and fairly present the data derived from such Studies. Except as disclosed in the Registration
Statement and the Prospectus, the Company has not received any written notices or other correspondence from the FDA or any other foreign,
federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA requiring the
termination or suspension of such Studies, other than ordinary course communications with respect to modifications in connection with
the design and implementation of such Studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxviii)
Except as would not result in a Material Adverse Effect, the Company (including its Subsidiaries) has not failed to file with the applicable
regulatory authorities (including the FDA or any foreign, federal, state or local governmental or regulatory authority performing functions
similar to those performed by the FDA and having jurisdiction over the Company) any filing, declaration, listing, registration, report
or submission that is required to be so filed for the Company&rsquo;s business operation as currently conducted. All such filings were
in material compliance with applicable laws when filed and no material deficiencies have been asserted in writing by any applicable regulatory
authority (including, without limitation, the FDA or any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA) with respect to any such filings, declarations, listings, registrations, reports or
submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxix)
The Registration Statement and the Prospectus identify each employment, severance or other similar agreement, arrangement or policy and
each material arrangement providing for insurance coverage, benefits, bonuses, stock options or other forms of incentive compensation,
or post-retirement insurance, compensation or benefits which: (i) is entered into, maintained or contributed to, as the case may be,
by the Company and (ii) covers any officer or director or former officer or former director of the Company, in each case to the extent
required by the Rules and Regulations. These contracts, plans and arrangements are referred to collectively in this Agreement as the
&ldquo;<B><I>Benefit Arrangements</I></B>.&rdquo; Each Benefit Arrangement has been maintained in material compliance with its terms
and with requirements prescribed by any and all statutes, orders, rules and regulations that are applicable to that Benefit Arrangement
in each case except where the failure to comply is not reasonably likely to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xl)
Except as set forth in the Registration Statement or the Prospectus, the Company is not a party to or subject to any employment contract
or arrangement providing for annual future compensation, or the opportunity to earn annual future compensation (whether through fixed
salary, bonus, commission, options or otherwise) of more than $120,000 to any executive officer or director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xli)
The conditions for use of Form S-3 to register the Offering under the Securities Act, as set forth in the General Instructions to such
Form, have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlii)
Except as disclosed in the Registration Statement and the Prospectus, neither the execution of this Agreement nor the consummation of
the Offering, constitutes a triggering event under any Benefit Arrangement or any other employment contract, whether or not legally enforceable,
which (either alone or upon the occurrence of any additional or subsequent event) will or may result in any payment (of severance pay
or otherwise), acceleration, increase in vesting or increase in benefits to any current or former participant, employee or director of
the Company other than an event that is not material to the financial condition or business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliii)
Neither the Company nor, to the Company&rsquo;s knowledge, any of its employees or agents, has at any time during the last three (3)
years: (i) made any unlawful contribution to any candidate for foreign office, or failed to disclose fully any contribution in violation
of law, or (ii) made any payment to any federal or state governmental officer or official or other person charged with similar public
or quasi-public duties in the United States, other than payments that are not prohibited by the laws of the United States or any jurisdiction
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliv)
The Company has not offered, or caused the Agent to offer, any Shares to any person or entity with the intention of unlawfully influencing:
(i) a supplier of the Company to alter the supplier&rsquo;s level or type of business with the Company or (ii) a journalist or publication
to write or publish favorable information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlv)
The operations of the Company are and have been conducted at all times in compliance in all material respects with applicable financial
record keeping and reporting requirements and money laundering statutes of the United States and, to the Company&rsquo;s knowledge, all
other applicable jurisdictions to which the Company is subject, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively, the &ldquo;<B><I>Money
Laundering Laws</I></B>&rdquo;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or
any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the Company&rsquo;s knowledge, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvi)
Neither the Company nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee or Affiliate of the Company is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<B><I>OFAC</I></B>&rdquo;);
and the Company will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such
proceeds to any joint venture partner or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvii)
None of the Company, its directors or officers or, to the Company&rsquo;s knowledge, any agent, employee, affiliate or other person acting
on behalf of the Company has engaged in any activities sanctionable under the Comprehensive Iran Sanctions, Accountability, and Divestment
Act of 2010, the Iran Sanctions Act of 1996, the National Defense Authorization Act for Fiscal Year 2012, the Iran Threat Reduction and
Syria Human Rights Act of 2012 or any Executive Order relating to any of the foregoing (collectively, and as each may be amended from
time to time, the &ldquo;<B><I>Iran Sanctions</I></B>&rdquo;); and the Company will not directly or indirectly use the proceeds of the
Offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity,
for the purpose of engaging in any activities sanctionable under the Iran Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlviii)
Except as described in the Registration Statement and the Prospectus, there are no claims, payments, arrangements, agreements or understandings
relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or any officer, director or stockholder of
the Company (each, an &ldquo;<B><I>Insider</I></B>&rdquo;) with respect to the sale of the Shares hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its stockholders that may affect the Agent&rsquo;s
compensation, as determined by FINRA. Except as described in the Registration Statement and the Prospectus, the Company has not made
any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee, consulting fee or otherwise,
in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital
to the Company; (ii) to any FINRA member participating in the offering as defined in FINRA Rule 5110 (a &ldquo;<B><I>Participating Member</I></B>&rdquo;);
or (iii) to any person or entity that has any direct or indirect affiliation or association with any Participating Member, within the
180 days prior to the commencement of sales of this offering. None of the Net Proceeds will be paid by the Company to any Participating
Member or its affiliates, except as specifically authorized herein. No officer, director or, to the Company&rsquo;s knowledge, any beneficial
owner of 10% or more of the Company&rsquo;s securities (whether debt or equity, registered or unregistered, regardless of the time acquired
or the source from which derived) (any such individual or entity, a &ldquo;<B><I>Company Affiliate</I></B>&rdquo;) has any direct or
indirect affiliation or association with any Participating Member (as determined in accordance with the rules and regulations of FINRA);
no Company Affiliate is an owner of stock or other securities of any Participating Member (other than securities purchased on the open
market); no Company Affiliate has made a subordinated loan to any Participating Member; and no Net Proceeds from the sale of the Shares
will be paid to any Participating Member, or any persons associated with or affiliated with any Participating Member. Except as disclosed
in the Registration Statement and the Prospectus, the Company has not issued any warrants or other securities or granted any options,
directly or indirectly, to any Participating Member within the 180-day period prior to the initial filing date of the Registration Statement;
no person to whom securities of the Company have been privately issued within the 180-day period prior to the initial filing date of
the Registration Statement has any relationship or affiliation or association with any Participating Member; and no Participating Member
in the offering has a conflict of interest with the Company. For this purpose, a &ldquo;conflict of interest&rdquo; has the meaning ascribed
to such term in FINRA Rule 5121(f)(5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlix)
There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;IT Systems and Data&rdquo;),
except as would not, individually, or in the aggregate have a Material Adverse Effect, and (y) the Company and the Subsidiaries have
not been notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach
or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,
internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such
IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate,
have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards
to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with
industry standards and practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company has not distributed and will not distribute any prospectus or other offering material in connection with the Offering other
than the Registration Statement and the Prospectus or other materials permitted by the Securities Act to be distributed by the Company;
provided, however, that the Company has not made and will not make any offer relating to the Shares that would constitute a &ldquo;free
writing prospectus&rdquo; as defined in Rule 405 under the Securities Act, except any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any certificate signed by any officer of the Company and delivered to the Agent or the Agent&rsquo;s counsel shall be deemed a representation
and warranty by the Company to Agent as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
At the effective date of the Registration Statement, each Bringdown Date (as hereinafter defined) and each Time of Sale, the Company
shall be deemed to have affirmed each representation and warranty contained in or made pursuant to this Agreement as of such date as
though made at and as of such date (except that such representations and warranties shall be deemed to relate to the Registration Statement
and the Prospectus as amended and supplemented relating to such Shares on such date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
As used in this Agreement, references to matters being &ldquo;<B><I>material</I></B>&rdquo; with respect to the Company shall mean a
material event, change, condition, status or effect related to the condition (financial or otherwise), properties, assets (including
intangible assets), liabilities, business, prospects, operations or results of operations of the Company, either individually or taken
as a whole, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
As used in this Agreement, the term &ldquo;<B><I>to the Company&rsquo;s knowledge</I></B>&rdquo; (or similar language) shall mean the
knowledge of the executive officers and directors of the Company who are named in the Prospectus, with the assumption that such executive
officers and directors shall have made reasonable and diligent inquiry of the matters presented (with reference to what is customary
and prudent for the applicable individuals in connection with the discharge by the applicable individuals of their duties as executive
officers or directors of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><I>Purchase, Sale and Delivery of Shares</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>At the Market Sales</I>. On the basis of the representations, warranties and agreements herein the Company agrees that, from time
to time after the effective date of the Registration Statement on the terms and subject to the conditions set forth herein, it may issue
and sell through the Agent, acting as sales agent, Shares having an aggregate offering price of up to $[___] (the &ldquo;<B><I>Offering
Size</I></B>&rdquo;); provided, however, that in no event shall the Company issue or sell through the Agent such number of Shares that
(a) exceeds the number or dollar amount of shares of Common Stock registered on the Registration Statement pursuant to which the Offering
is being made, (b) exceeds the number of authorized but unissued shares of Common Stock under the Company&rsquo;s Amended and Restated
Certificate of Incorporation, as amended or (c) would cause the Company or the Offering to not satisfy the eligibility and transaction
requirements for use of Form S-3 (including, if then applicable, General Instruction I.B.6 of Form S-3) (the lesser of (a), (b) and (c),
the &ldquo;<B><I>Maximum Amount</I></B>&rdquo;). Notwithstanding anything to the contrary contained herein, the parties hereto agree
that compliance with the limitations set forth in this Section 2(a) on the number and aggregate sales price of Shares issued and sold
under this Agreement shall be the sole responsibility of the Company and the Agent shall have no obligation in connection with such compliance.
Notwithstanding the foregoing, the Company agrees that it will provide the Agent with written notice of the Maximum Amount available
for sale of the Shares no less than one (1) Business Day prior to the date on which it makes the initial sale of Shares under this Agreement.
&ldquo;<B><I>Business Day</I></B>&rdquo;, as used herein, shall mean any day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to remain closed; provided that banks shall not be deemed to be authorized
or obligated to be closed due to a &ldquo;shelter in place,&rdquo; &ldquo;non-essential employee&rdquo; or similar closure of physical
branch locations at the direction of any governmental authority if such banks&rsquo; electronic funds transfer systems (including for
wire transfers) are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
For purposes of selling the Shares through the Agent, the Company hereby appoints the Agent as agent of the Company (including in the
event the Company increases the Offering Size) for the purpose of soliciting purchases of the Shares from the Company pursuant to this
Agreement and the Agent agrees to use its commercially reasonable efforts to sell the Shares on the terms and subject to the conditions
stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Each time the Company wishes to issue and sell the Shares hereunder (each, a &ldquo;<B><I>Transaction</I></B>&rdquo;), it will notify
the Agent by telephone (confirmed promptly by e-mail to the appropriate individual listed on <U>Schedule D</U> hereto, using a form substantially
similar to that set forth on <U>Schedule C</U> hereto) (a &ldquo;<B><I>Transaction Notice</I></B>&rdquo;) as to the maximum number of
Shares to be sold by the Agent on such day and in any event not in excess of the amount available for issuance under the Prospectus and
the currently effective Registration Statement, the time period during which sales are requested to be made, any limitation on the number
of shares that may be sold in any one Trading Day (as defined below), and any minimum price below which sales may not be made. The Transaction
Notice shall originate from any of the individuals from the Company set forth on <U>Schedule B</U> (with a copy to each of the other
individuals from the Company listed on such Schedule), and shall be addressed to each of the individuals from the Agent set forth on
<U>Schedule D</U>, as such <U>Schedule D</U> may be amended from time to time. Subject to the terms and conditions hereof and unless
the sale of the Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement,
the Agent shall promptly acknowledge the Transaction Notice by e-mail (or by some other method mutually agreed to in writing by the parties)
and shall use its commercially reasonable efforts to sell all of the Shares so designated by the Company in the Transaction Notice and
in accordance with the terms set forth herein; provided, however, that any obligation of the Agent to use such commercially reasonable
efforts shall be subject to the continuing accuracy of the representations and warranties of the Company herein, to the performance by
the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions specified in <U>Section 4</U>
of this Agreement. The gross sales price of the Shares sold under this <U>Section 2(a)</U> shall be equal to the market price for the
Common Stock sold by the Agent under this <U>Section 2(a)</U> on the NYSE American at the time of such sale. For the purposes hereof,
&ldquo;<B><I>Trading Day</I></B>&rdquo; means any day on which shares of Common Stock are purchased and sold on the principal market
on which the Common Stock is listed or quoted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company or the Agent may, upon notice to the other party hereto by telephone (confirmed promptly by e-mail to the respective individuals
of the other party set forth on <U>Schedule D</U> hereto, which confirmation shall be promptly acknowledged by the other party), suspend
the Offering for any reason and at any time, whereupon the Agent shall so suspend the offering of Shares until further notice is provided
by the other party to the contrary; <I>provided</I>, <I>however</I>, that such suspension or termination shall not affect or impair the
parties&rsquo; respective obligations with respect to the Shares sold hereunder prior to the receipt by the Agent of such notice. Each
of the parties agrees that no such notice under this <U>Section 2(a)(iii)</U> shall be effective against the other unless it is made
to one of the individuals named on <U>Schedule D</U> hereto, as such Schedule may be amended from time to time. Notwithstanding the foregoing,
if the Agent suspends the Offering for any three (3) consecutive Business Days or on more than three (3) separate occasions (in each
instance other than as a result of the Company&rsquo;s breach of its obligations hereunder), the Company, in its sole discretion, may
elect to terminate this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in selling the Shares, (B) the
Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for any reason other
than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable
law and regulations to sell such Shares as required under this Agreement, and (C) the Agent shall be under no obligation to purchase
shares on a principal basis pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Agent may sell Shares by any method permitted by law to be an &ldquo;at-the-market offering&rdquo; as defined in Rule 415 of the
Securities Act including without limitation sales made directly on the NYSE American, on any other existing trading market for the Common
Stock or to or through a market maker. With the prior written consent of the Company, which may be provided in a Transaction Notice,
the Agent may also sell Shares in privately negotiated transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The compensation to the Agent for sales of the Shares, as an agent of the Company, shall be 3.0% (the &ldquo;<B><I>Transaction Fee</I></B>&rdquo;)
of the gross sales price of all of Shares sold pursuant to this <U>Section 2(a)</U>. The remaining proceeds, after further deduction
for any transaction or other fees imposed by any governmental or self-regulatory organization in respect of such sales, shall constitute
the net proceeds to the Company for such Shares (the &ldquo;<B><I>Net Proceeds</I></B>&rdquo;). The Agent shall notify the Company as
promptly as practicable if any deduction referenced in the preceding sentence will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
The Agent shall provide written confirmation to the Company following the close of trading on the NYSE American each day in which the
Shares are sold under this <U>Section 2(a)</U> setting forth the number of the Shares sold on such day, the aggregate gross sale proceeds,
the Net Proceeds to the Company, and the compensation payable by the Company to the Agent with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
All Shares sold pursuant to this <U>Section 2(a)</U> will be delivered by the Company to Agent for the accounts of the Agent on the first
full Business Day following the date on which such Shares are sold, or at such other time and date as Agent and the Company determine
pursuant to Rule 15c6-1(a) under the Exchange Act, each such time and date of delivery being herein referred to as a &ldquo;<B><I>Settlement
Date</I></B>.&rdquo; On each Settlement Date, the Shares sold through the Agent for settlement on such date shall be issued and delivered
by the Company to the Agent against payment of the Net Proceeds from the sale of such Shares. Settlement for all such Shares shall be
effected by free delivery of the Shares by the Company or its transfer agent (i) to the Agent or its designee&rsquo;s account (provided
the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company
(&ldquo;<B><I>DTC</I></B>&rdquo;) or (ii) by such other means of delivery as may be mutually agreed upon by the parties hereto, which
in all cases shall be freely tradable, transferable, registered shares in good deliverable form, in return for payment in same day funds
delivered to an account designated by the Company. If the Company or its transfer agent (if applicable) shall default on its obligation
to deliver the Shares on any Settlement Date, the Company shall (A) indemnify and hold the Agent harmless against any loss, claim or
damage arising from or as a result of such default by the Company and (B) pay the Agent any commission to which it would otherwise be
entitled absent such default. If the Agent breaches this Agreement by failing to deliver the Net Proceeds on any Settlement Date for
the shares delivered by the Company, the Agent will pay the Company interest based on the effective prime rate until such proceeds, together
with such interest, have been fully paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Under no circumstances shall the Company cause or request the offer or sale of any Shares if, after giving effect to the sale of such
Shares, the aggregate gross sales proceeds sold pursuant to this Agreement would exceed the lesser of (A) together with all sales of
Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration
Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of
directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under
no circumstances shall the Company cause or request the offer or sale of any Shares at a price lower than the minimum price authorized
from time to time by the Company&rsquo;s board of directors, duly authorized committee thereof or a duly authorized executive committee,
and notified to the Agent in writing. Further, under no circumstances shall the aggregate offering amount of Shares sold pursuant to
this Agreement exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of Shares in the Offering shall only be
effected by or through the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Nothing herein contained shall constitute the Agent an unincorporated association or partner with the Company. Under no circumstances
shall any Shares be sold pursuant to this Agreement after the date which is three years after the Registration Statement was first declared
effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding any other provisions of this Agreement, the Company agrees that no sale of Shares shall take place, and the Company shall
not request the sale of any Shares, and the Agent shall not be obligated to sell, during any period in which the Company is, or could
be deemed to be, in possession of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Unless the exceptive provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act are satisfied with respect to the
Shares, the Company shall give the Agent at least one Business Day&rsquo;s prior notice of its intent to sell any Shares in order to
allow the Agent time to comply with Regulation M.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><I><U>Covenants</U></I></B>. The Company covenants and agrees with the Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
After the date hereof and through any Prospectus Delivery Period, prior to amending or supplementing the Registration Statement (including
any Rule 462(b) Registration Statement), Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus related to changes
in this Agreement, the Company shall furnish to the Agent for review a copy of each such proposed amendment or supplement, allow the
Agent a reasonable amount of time to review and comment on such proposed amendment or supplement, and the Company shall not file any
such proposed amendment or supplement to which the Agent or counsel to the Agent reasonably object; provided that the foregoing shall
not apply with regards to the filing by the Company of any Form 10-K, 10-Q, 8-K, proxy statement or other Incorporated Document. Subject
to this <U>Section 3(a)</U>, immediately following execution of this Agreement, if not previously prepared, the Company will prepare
a prospectus supplement describing the selling terms of the Shares hereunder, the plan of distribution thereof and such other information
as may be required by the Securities Act or the Rules and Regulations or as the Agent and the Company may deem appropriate, and if requested
by the Agent, a Permitted Free Writing Prospectus containing the selling terms of the Shares hereunder and such other information as
the Company and the Agent may deem appropriate, and will file or transmit for filing with the Commission, in accordance with Rule 424(b)
or Rule 433, as the case may be, copies of the Prospectus as supplemented and each such Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests
for additional or supplemental information from, the Commission (including, for the avoidance of doubt, as it relates to the effectiveness
of the Registration Statement) or for any amendments or supplements to the Registration Statement, the Base Prospectus, the Prospectus
or any Permitted Free Writing Prospectus (excluding any Incorporated Documents), (ii) of the time and date of any filing of any post-effective
amendment to the Registration Statement or any amendment or supplement to any Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus (excluding any Incorporated Documents), (iii) of the time and date that any post-effective amendment to the Registration Statement
becomes effective, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto or of any order preventing or suspending its use or the use of any Base Prospectus, the Prospectus
or any Permitted Free Writing Prospectus, or (v) of any proceedings to remove, suspend or terminate from listing or quotation the Common
Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening
or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company
will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that
it shall comply with the provisions of Rules 424(b), 430B and 430C, as applicable, under the Securities Act and will use its reasonable
efforts to confirm that any filings made by the Company under Rule 424(b), Rule 433 or Rule 462 were received in a timely manner by the
Commission (without reliance on Rule 424(b)(8) or Rule 164(b)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
From the date hereof through the later of (A) the termination of this Agreement and (B) the end of any applicable Prospectus Delivery
Period, the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as now and hereafter
amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act so far as necessary to permit the continuance
of sales of or dealings in the Shares as contemplated by the provisions hereof, the Base Prospectus, the Prospectus and any Permitted
Free Writing Prospectus. If during any applicable Prospectus Delivery Period any event occurs as a result of which the Base Prospectus,
the Prospectus, or any Permitted Free Writing Prospectus would include an untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during any applicable
Prospectus Delivery Period it is necessary or appropriate in the opinion of the Company or its counsel or in the reasonable opinion of
the Agent or counsel to the Agent to amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted
Free Writing Prospectus, to comply with the Securities Act or to file under the Exchange Act any document which would be deemed to be
incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, the Company will promptly
notify Agent (or the Agent will notify the Company, as applicable), and the Agent shall suspend the offering and sale of any such Shares,
and the Company will amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance
within the time period prescribed by the Securities Act or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
In case the Agent is required to deliver (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), in connection with the sale of the Shares, a Prospectus after the nine-month period referred to in Section 10(a)(3) of the Securities
Act, or after the time a post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation S-K
under the Securities Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration
Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Securities Act
or Item 512(a) of Regulation S-K under the Securities Act, as the case may be. The Company shall cause each amendment or supplement to
any Base Prospectus or the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b)
of the Securities Act or, in the case of any document which would be deemed to be incorporated by reference therein, to be filed with
the Commission as required pursuant to the Exchange Act, within the time period prescribed. The Company shall promptly notify the Agent
if any Material Contract is terminated or if the other party thereto gives written notice of its intent to terminate any such Material
Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If at any time following issuance of a Permitted Free Writing Prospectus there occurs an event or development as a result of which such
Permitted Free Writing Prospectus would conflict with the information contained in the Registration Statement, the Base Prospectus or
the Prospectus, or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company
promptly will notify the Agent and will promptly amend or supplement, at its own expense, such Permitted Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall use commercially reasonable efforts to take or cause to be taken all necessary action to qualify the Shares for sale
under the securities laws of such jurisdictions as Agent reasonably designates and to continue such qualifications in effect so long
as required for the distribution of the Shares, except that the Company shall not be required in connection therewith to qualify as a
foreign corporation or to execute a general consent to service of process in any state. The Company shall promptly advise the Agent of
the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company will furnish to the Agent and counsel for the Agent, to the extent requested, copies of the Registration Statement, the Base
Prospectus, the Prospectus, any Permitted Free Writing Prospectus, and all amendments and supplements to such documents, in each case
as soon as available and in such quantities as the Agent may from time to time reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company will make generally available to its security holders as soon as practicable an earnings statement (which need not be audited)
covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.
If the Company makes any public announcement or release disclosing its results of operations or financial condition for a completed quarterly
or annual fiscal period (each, an &ldquo;<B><I>Earnings Release</I></B>&rdquo;) and the Company has not yet filed an Annual Report on
Form 10-K or a Quarterly Report on Form 10-Q or a Form 8-K with respect to such information, as applicable, then, prior to any sale of
Shares, the Company shall be obligated to (x) file a prospectus supplement with the Commission under the applicable paragraph of Rule
424(b), which prospectus supplement shall include the applicable financial information or (y) file a Report on Form 8-K, which Form 8-K
shall include the applicable financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause
to be paid (i) all expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred
in connection with the registration, issue, sale and delivery of the Shares, (ii) all reasonable expenses and fees (including, without
limitation, fees and expenses of the Company&rsquo;s accountants and counsel) in connection with the preparation, printing, filing, delivery,
and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto),
the Base Prospectus, each Prospectus, any Permitted Free Writing Prospectus, and any amendment thereof or supplement thereto, and the
producing, word-processing, printing, delivery, and shipping of this Agreement and other closing documents, including blue sky memoranda
(covering the states and other applicable jurisdictions) and including the cost to furnish copies of each thereof to the Agent, (iii)
all filing fees, (iv) listing fees, if any, and (v) all other costs and expenses of the Company incident to the performance of its obligations
hereunder that are not otherwise specifically provided for herein (including the costs and expenses related to any investor presentations
or &ldquo;roadshow&rdquo; undertaken in connection with marketing of the Shares as agreed to by the Company). The Company shall reimburse
the Agent upon request for its actual, reasonable and documented costs and out-of-pocket expenses incurred in connection with this Agreement,
whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, including the actual, reasonable
and documented fees and out-of-pocket expenses of its legal counsel up to $50,000. In addition, the Company shall pay the Agent $5,000
for its legal fees for each Bringdown Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company will apply the net proceeds from the sale of the Shares in the manner set forth under the caption &ldquo;Use of Proceeds&rdquo;
in the Base Prospectus, the Prospectus, and any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
During each period commencing on the date of each Transaction Notice and ending after the close of business on the Settlement Date for
the related transactions covered by such Transaction Notice, the Company will not offer for sale, sell, contract to sell, pledge, grant
any option for the sale of, enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition
(whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company or any Subsidiary,
or otherwise issue or dispose of, directly or indirectly (or publicly disclose the intention to make any such offer, sale, pledge, grant,
issuance or other disposition), of any Common Stock or any securities convertible into or exchangeable for, or any options or rights
to purchase or acquire, Common Stock, or permit the registration under the Securities Act of any Common Stock, such securities, options
or rights, except for (i) the registration of the Shares and the sales through the Agent pursuant to this Agreement, (ii) the issuance
of securities issuable upon exercise or conversion of any options, convertible preferred stock, convertible notes and warrants that are
outstanding as of the date of this Agreement and described in the Registration Statement and the Prospectus, (iii) a registration statement
on Form S-8 relating to employee benefit plans and (iv) the issuance of securities pursuant to any employee stock incentive plan, stock
ownership plan or employee stock purchase plan of the Company in effect at the time of this Agreement or any compensatory inducement
grants made by the Company and approved by the Board consistent with past practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall not, at any time at or after the execution of this Agreement, offer or sell any of the Shares pursuant to this Agreement
by means of any &ldquo;prospectus&rdquo; (within the meaning of the Securities Act), or use any &ldquo;prospectus&rdquo; (within the
meaning of the Securities Act) in connection with the offer or sale of the Shares pursuant to this Agreement, in each case other than
the Prospectus or any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to
cause or result in, or which has constituted, (i) the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares or (ii) a violation of Regulation M. The Company shall notify the Agent of any violation of Regulation
M by the Company or any of its officers or directors promptly after the Company has received notice or obtained knowledge of any such
violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company will not incur any liability for any finder&rsquo;s or broker&rsquo;s fee or agent&rsquo;s commission in connection with
the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or thereby, except as contemplated
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
During any applicable Prospectus Delivery Period, the Company will file on a timely basis with the Commission such periodic and current
reports as required by the Rules and Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company has maintained, and will maintain, such controls and procedures, including without limitation those required by Sections
302 and 906 of Sarbanes-Oxley and the applicable regulations thereunder, that are designed to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Commission&rsquo;s rules and forms, including without limitation, controls and procedures designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the Company&rsquo;s management, including its principal executive officer and its principal financial
officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that
material information relating to Company is made known to them by others within those entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
Intentionally omitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
Each of the Company and Agent hereby represent and agree that, neither the Company nor the Agent has made nor will make any offer relating
to the Shares that would constitute an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 under the Securities Act,
or that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405 under the Securities Act, required
to be filed with the Commission other than a Permitted Free Writing Prospectus. The Company represents that it has treated or agrees
that it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433,
and has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely
Commission filing where required, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
(1) On the date hereof, the Company shall cause (A) Silverman Shin &amp; Schneider PLLC, counsel for the Company, to furnish to the Agent
its written opinion and negative assurance letter, in form and substance reasonably acceptable to Agent&rsquo;s counsel and (B) Studebaker
&amp; Brackett PC, intellectual property legal counsel to the Company, to furnish to the Agent its written opinion, in form and substance
reasonably acceptable to Agent&rsquo;s counsel, and the Agent shall cause (C) Ellenoff Grossman &amp; Schole LLP, as counsel for the
Agent to furnish to the Agent its negative assurance letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
On each date that the Company (i) amends or supplements the Registration Statement after the effective date of the Registration Statement
or the Prospectus (other than by means of incorporation by reference); (ii) files an annual report on Form 10-K under the Exchange Act;
(iii) files its quarterly reports on Form 10-Q under the Exchange Act; (iv) files a report on Form 8-K under the Exchange Act containing
amended financial information (other than an earnings release, to &ldquo;furnish&rdquo; information pursuant to Items 2.02 or 7.01 of
Form 8-K, unless the Agent reasonably determines that the information in such Form 8-K is material); or (v) otherwise after each reasonable
request by Agent (each of such date referred to herein as a &ldquo;<B><I>Bringdown Date</I></B>&rdquo;), the Company shall cause (X)
Silverman Shin &amp; Schneider PLLC, counsel for the Company, to furnish to the Agent its opinion and negative assurance letter, in form
and substance reasonably acceptable to Agent&rsquo;s counsel, and (Y) Studebaker &amp; Brackett PC, intellectual property legal counsel
to the Company, to furnish to the Agent its written opinion, in form and substance reasonably acceptable to Agent&rsquo;s counsel, and
the Agent shall cause (Z) Ellenoff Grossman &amp; Schole LLP, as counsel for the Agent to furnish to the Agent its negative assurance
letter, each dated as of a date within ten (10) days after the applicable Bringdown Date, addressed to the Agent and modified as necessary
to relate to the Registration Statement and the Prospectus as amended and supplemented to the time of delivery of such opinions. With
respect to this <U>Section 3(q)(2)</U>, in lieu of delivering such opinions or letters for Bringdown Dates subsequent to the date of
effectiveness of the Registration Statement, such counsel may furnish agent with a letter (a &ldquo;<B><I>Reliance Letter</I></B>&rdquo;)
to the effect that Agent may rely upon a prior opinion or letter delivered under <U>Section 3(q)(1)</U> or this <U>Section 3(q)(2)</U>
to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate
to the Registration Statement and the Prospectus as amended or supplemented as of the date of Reliance Letter). Provided, however, the
requirement to provide opinions and letters under this <U>Section 3(q)(2)</U> is hereby waived for any Bringdown Date occurring at a
time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers
a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company subsequently decides
to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide Agent with opinions and letters
under this <U>Section 3(q)(2)</U>, then before the Company delivers the Transaction Notice or Agent sells any Shares, the Company shall
cause each of Silverman Shin &amp; Schneider PLLC to furnish to the Agent a written opinion and negative assurance letter, and Studebaker
&amp; Brackett PC to furnish to the agent its written opinion, and the Agent shall cause Ellenoff Grossman &amp; Schole LLP to furnish
to the Agent its negative assurance letter, dated the date of the Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
On or prior to the effective date of the Registration Statement and within ten (10) days after each Bringdown Date, the Company shall
cause the Auditor, or other independent accountants satisfactory to the Agent, to deliver to the Agent (x) a customary comfort letter
(the initial letter, the &ldquo;<B><I>Initial Comfort Letter</I></B><I>,</I>&rdquo; and each subsequent letter, a &ldquo;<B><I>Bringdown
Comfort Letter</I></B>&rdquo;) addressed to Agent, in form and substance satisfactory to Agent, confirming that they are independent
public accountants within the meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications
of accountants under Rule 2-01 of Regulation S-X of the Commission, and stating the conclusions and findings of said firm with respect
to the financial information and other matters and (y) a letter updating the Initial Comfort Letter with any information that would have
been included in the Initial Comfort Letter had it been given on such date and as modified as necessary to relate to the date of such
letter. Provided, however, the requirement to provide a Bringdown Comfort Letter under this <U>Section 3(r)</U> is hereby waived for
any Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur
of the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing,
if the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide
Agent with a Bringdown Comfort Letter under this <U>Section 3(r)</U>, then before the Company delivers the Transaction Notice or Agent
sells any Shares, the Company shall cause the Auditor, or other independent accountants satisfactory to the Agent, to deliver to the
Agent a Bringdown Comfort Letter dated the date of the Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
On or prior to the effective date of the Registration Statement and each Bringdown Date, the Company shall furnish to the Agent an officer&rsquo;s
certificate, dated as of a date within ten (10) days after the applicable Bringdown Date and addressed to Agent, signed by the chief
executive officer and by the chief financial officer of the Company, to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The representations and warranties of the Company in this Agreement are true and correct in all material respects as if made at and as
of the date of the certificate, and the Company has complied in all material respects with all the agreements and satisfied all the conditions
on its part to be performed or satisfied at or prior to the date of the certificate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
No stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof
or the qualification of the Shares for offering or sale or notice that would prevent use of the Registration Statement, nor suspending
or preventing the use of the Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, has been issued, and no proceeding
for that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory
body;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Shares to be sold on that date have been duly and validly authorized by the Company and all corporate action required to be taken
for the authorization, issuance and sale of the Shares on that date has been validly and sufficiently taken;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Subsequent to the respective dates as of which information is given in the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus, as amended and supplemented, and except for pending transactions disclosed therein, the Company has not incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions, not in the ordinary course of business,
or declared or paid any dividends or made any distribution of any kind with respect to its capital stock, and there has not been any
change in the capital stock or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock
(other than as a result of the exercise of any currently outstanding options, warrants, preferred stock and notes that are disclosed
in the Registration Statement or the Prospectus or the issuance of securities pursuant to the Company&rsquo;s equity incentive plans
or employee stock purchase plans described in the Registration Statement or the Prospectus), or any material change in the short-term
or long-term debt, of the Company, or any Material Adverse Effect or any development that would reasonably be likely to result in a Material
Adverse Effect (whether or not arising in the ordinary course of business), or any material loss by strike, fire, flood, earthquake,
accident or other calamity, whether or not covered by insurance, incurred by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Except as stated in the Prospectus and any Permitted Free Writing Prospectus, as amended and supplemented, there is not pending, or,
to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company is a party before or
by any court or governmental agency, authority or body, or any arbitrator, which would reasonably be likely to result in any Material
Adverse Effect; provided, however, the requirement to provide a certificate under this <U>Section 3(s)</U> is hereby waived for any Bringdown
Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date
the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company
subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide Agent with
a certificate under this <U>Section 3(s)</U>, then before the Company delivers the Transaction Notice or Agent sells any Shares, the
Company shall provide Agent with a certificate dated the date of the Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
A reasonable time prior to each Bringdown Date, the Company, if so requested by the Agent, shall conduct a due diligence session, in
form and substance, satisfactory to the Agent, which shall include representatives of the management and the accountants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
The Company shall disclose in its annual report on Form 10-K and its quarterly reports on Form 10-Q the number of Shares sold through
the Agent under this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to sales of the
Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Company shall ensure that there are at all times sufficient shares of Common Stock to provide for the issuance, free of any preemptive
rights, out of its authorized but unissued Common Stock, of the maximum aggregate number of Shares authorized for issuance by the Board
pursuant to the terms of this Agreement. The Company will use its reasonable best efforts to cause the Shares to be listed on the NYSE
American, and to maintain such listing. The Company shall cooperate with Agent and use its reasonable efforts to permit Shares to be
eligible for clearance and settlement through the facilities of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
At any time during the term of this Agreement, the Company will advise the Agent promptly after it receives notice or obtains knowledge
of any information or fact that would alter or affect any opinion, certificate, letter and other document provided to the Agent pursuant
to <U>Section 3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
Subject to compliance with any applicable requirements of Regulation M under the Exchange Act and compliance with applicable securities
laws, the Company consents to the Agent trading in the Common Stock for the Agent&rsquo;s own account and for the account of its clients
(in compliance with all applicable laws) at the same time as sales of the Shares occur pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
If to the knowledge of the Company, any condition set forth in <U>Section 4</U> shall not have been satisfied on the applicable Settlement
Date or will not be satisfied on or prior to the date required by this Agreement, the Company will offer to any person who has agreed
to purchase the Shares on such Settlement Date from the Company as the result of an offer to purchase solicited by the Agent the right
to refuse to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
On or prior to the effective date of the Registration Statement and each Bringdown Date, the Company shall furnish to the Agent a certificate
from the Company&rsquo;s corporate secretary certifying: (i) that each of the Amended and Restated Certificate of Incorporation and Restated
and Amended Bylaws is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions of the Board
relating to the Offering are in full force and effect and have not been modified; (iii) the good standing of the Company; and (iv) as
to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
Each acceptance by the Company of an offer to purchase the Shares hereunder shall be deemed to be an affirmation to the Agent that the
representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of
such acceptance as though made at and as of such date, and an undertaking that such representations and warranties will be true and correct
as of the Settlement Date for the Shares relating to such acceptance, as though made at and as of such date (except that such representations
and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such
Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
During any period when the delivery of a prospectus relating to the Shares is required (including in circumstances where such requirement
may be satisfied pursuant to Rule 172, 173 or any similar rule) to be delivered under the Securities Act, the Company will file all documents
required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and the regulations
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
The Company shall cooperate with Agent and use its reasonable efforts to permit the Shares to be eligible for clearance and settlement
through the facilities of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
The Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
To the extent that the Registration Statement is not available for the sales of the Shares as contemplated by this Agreement, the Company
shall file a new registration statement with respect to any additional shares of Common Stock necessary to complete such sales of the
Shares and shall cause such registration statement to become effective as promptly as practicable. After the effectiveness of any such
registration statement, all references to &ldquo;Registration Statement&rdquo; included in this Agreement shall be deemed to include
such new registration statement, including all documents incorporated by reference therein pursuant to Item 12 of Form S-3, and all references
to &ldquo;Base Prospectus&rdquo; included in this Agreement shall be deemed to include the final form of prospectus, including all documents
incorporated therein by reference, included in any such registration statement at the time such registration statement became effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
During the term of the Agreement, the Company will provide the Agent with prompt notice of any planned offering of its equity, equity-linked
or debt securities to permit the Agent to determine if and when sales under the Agreement must be suspended. The Agent shall use its
best efforts to provide consent to such planned offering with in one (1) day after receipt of such notice but in no event later than
five (5) business days after receipt of such notice. The Company covenants and agrees that until the Agent has provided consent, the
Company shall not commence any such planned offering, provided that after such five (5) business day period the Company may proceed with
such offering without the Agent&rsquo;s consent. Notwithstanding the foregoing, the Company shall not be required to provide notice to
the Agent with respect to its entry into an equity line of credit, provided, however, the Company shall still be required to comply with
all the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B><I>Conditions of Agent&rsquo;s Obligations</I></B>. The obligations of the Agent hereunder are subject to (i) the accuracy of, as
of the date hereof, each Bringdown Date, and each Time of Sale (in each case, as if made at such date), and compliance with, all representations,
warranties and agreements of the Company contained herein, (ii) the performance by the Company of its obligations hereunder and (iii)
the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If filing of the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing Prospectus, is required under the
Securities Act or the Rules and Regulations, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted
Free Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8)
or Rule 164(b)); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement
or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Base
Prospectus, the Prospectus or any Permitted Free Writing Prospectus shall have been issued; no proceedings for the issuance of such an
order shall have been initiated or threatened; and any request of the Commission for additional information (to be included in the Registration
Statement, the Base Prospectus, the Prospectus, any Permitted Free Writing Prospectus or otherwise) shall have been complied with to
the Agent&rsquo;s satisfaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Agent shall not have advised the Company that the Registration Statement, the Base Prospectus, the Prospectus, or any amendment or
supplement thereto, or any Permitted Free Writing Prospectus, contains an untrue statement of fact which, in the Agent&rsquo;s opinion,
is material, or omits to state a fact which, in the Agent&rsquo;s opinion, is material and is required to be stated therein or is necessary
to make the statements therein (i) with respect to the Registration Statement, not misleading and (ii) with respect to the Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth or contemplated in the Prospectus and any Permitted Free Writing Prospectus, subsequent to the respective dates as
of which information is given therein, the Company shall not have incurred any material liabilities or obligations, direct or contingent,
or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its
capital stock and there shall not have been any change in the capital stock, or any issuance of options, warrants, convertible securities
or other rights to purchase the capital stock (other than as a result of the exercise of any currently outstanding options, preferred
stock, notes or warrants that are disclosed in the Registration Statement or the Prospectus or the issuance of securities pursuant to
the Company&rsquo;s equity incentive plans or employee stock purchase plans described in the Registration Statement or the Prospectus),
or any material change in the short-term or long-term debt, of the Company, or any Material Adverse Effect or any development that would
be reasonably likely to result in a Material Adverse Effect (whether or not arising in the ordinary course of business), or any material
loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company, the
effect of which, in any such case described above, in the Agent&rsquo;s judgment, makes it impractical or inadvisable to offer or deliver
the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall have performed each of its obligations under <U>Section 3(q)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company shall have performed each of its obligations under <U>Section 3(r)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company shall have performed each of its obligations under <U>Section 3(s)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
All filings with the Commission required by Rule 424 under the Securities Act to have been filed by the Settlement Date shall have been
made within the applicable time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company shall have furnished to Agent and the Agent&rsquo;s counsel such additional documents, certificates and evidence as they
may have reasonably requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Trading in the Common Stock shall not have been suspended on the NYSE American. The Shares shall have been listed and authorized for
trading on the NYSE American prior to the first Settlement Date, and satisfactory evidence of such actions shall have been provided to
the Agent and its counsel, which may include oral confirmation from a representative of the NYSE American.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
On the effective date of the Registration Statement and each Bringdown Date, Ellenoff Grossman &amp; Schole LLP, counsel for the Agent,
shall not have reasonably determined that the Base Prospectus, the Prospectus, or any Permitted Free Writing Prospectus, as of such date,
includes an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in the light
of the circumstances then existing, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
such opinions, certificates, letters and other documents will be in compliance with the provisions hereof only if they are reasonably
satisfactory in form and substance to Agent and the Agent&rsquo;s counsel. The Company will furnish Agent with such conformed copies
of such opinions, certificates, letters and other documents as Agent shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B><I>Indemnification and Contribution</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to indemnify and hold harmless the Agent and each of the other Indemnified Parties (as defined below) from and against
any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements, and any and all
actions suits proceedings and investigations in respect thereof and any and all legal and other costs, expenses and disbursements in
giving testimony or furnishing documents in response to subpoena or otherwise (including, without limitation, the costs, expenses and
disbursements, as and when incurred, of investigating, preparing, pursuing or defending any such action, suit, proceeding or investigation
(whether or not in connection with litigation in which any Indemnified Party is a party)) (collectively, &ldquo;<B><I>Losses</I></B>&rdquo;),
directly or indirectly, caused by, relating to, based upon, arising out of, or in connection with this Agreement, including, without
limitation, any act or omission by the Agent in connection with its acceptance of or the performance or non-performance of its obligations
under the Agreement, any breach by the Company of any representation, warranty, covenant or agreement contained in the Agreement (or
in any instrument, document or agreement relating thereto, including any agency agreement), or the enforcement by the Agent of its rights
under the Agreement or these indemnification provisions, except to the extent that any such Losses are found in a final judgment by a
court of competent jurisdiction (not subject to further appeal) to have resulted primarily and directly from the gross negligence or
willful misconduct of the Indemnified Party seeking indemnification hereunder. The Company also agrees that no Indemnified Party shall
have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with this Agreement
for any other reason, except to the extent that any such liability is found in a final judgment by a court of competent jurisdiction
(not subject to further appeal) to have resulted primarily and directly from such Indemnified Party&rsquo;s gross negligence or willful
misconduct This indemnity agreement will be in addition to any liability that the Company otherwise might have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
These indemnification provisions shall extend to the following persons (collectively, the &ldquo;<B><I>Indemnified Parties</I></B>&rdquo;):
the Agent, its present and former affiliated entities, managers, members, officers, employees, legal counsel, agents and controlling
persons (within the meaning of the federal securities laws), and the officers, directors, partners, stockholders, members, managers,
employees, legal counsel, agents and controlling persons of any of them. These indemnification provisions shall be in addition to any
liability which the Company may otherwise have to any Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If any action, suit, proceeding or investigation is commenced, as to which an Indemnified Party proposes to demand indemnification, it
shall notify the Company with reasonable promptness; <U>provided</U>, <U>however</U>, that any failure by an Indemnified Party to notify
the Company shall not relieve the Company from its obligations hereunder except to the extent that the Company is actually and materially
prejudiced by such failure to notify. An Indemnified Party shall have the right to retain counsel of its own choice to represent it,
and the fees, expenses and disbursements of such counsel shall be borne by the Company. Any such counsel shall, to the extent consistent
with its professional responsibilities, cooperate with the Company and any counsel designated by the Company. The Company shall be liable
for any settlement of any claim against any Indemnified Party made with the Company&rsquo;s written consent. The Company shall not, without
the prior written consent of the Agent, settle or compromise any claim, or permit a default or consent to the entry of any judgment in
respect thereof, unless such settlement, compromise or consent (i) includes, as an unconditional term thereof, the giving by the claimant
to all of the Indemnified Parties of an unconditional release from all liability in respect of such claim, and (ii) does not contain
any factual or legal admission by or with respect to an Indemnified Party or an adverse statement with respect to the character, professionalism,
expertise or reputation of any Indemnified Party or any action or inaction of any Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
In order to provide for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions
is made but it is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification
may not be enforced in such case, even though the express provisions hereof provide for indemnification in such case, then the Company
shall contribute to the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received by
the Company and its stockholders, Subsidiaries and affiliates, on the one hand, and the Indemnified Party, on the other hand, and (ii)
if (and only if) the allocation provided in clause (i) of this sentence is not permitted by applicable law, in such proportion as to
reflect not only the relative benefits, but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the
other hand, in connection with the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations.
No person found liable for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable
for fraudulent misrepresentation. The relative benefits received (or anticipated to be received) by the Company and its stockholders,
Subsidiaries and affiliates shall be deemed to be equal to the aggregate consideration payable or receivable by such parties in connection
with the transaction or transactions to which the Agreement relates relative to the amount of fees actually received by the Agent in
connection with such transaction or transactions. Notwithstanding the foregoing, in no event shall the amount contributed by all Indemnified
Parties exceed the amount of fees previously received by the Agent pursuant to the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
(i) The Agent will indemnify and hold harmless the Company and its affiliates and directors and each officer of the Company who signed
the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act (the &ldquo;<B><I>Company Indemnified Parties</I></B>&rdquo;) from and against any Losses to which the
Company or the Company Indemnified Parties may become subject, under the Securities Act or otherwise (including in settlement of any
litigation, if such settlement is effected with the written consent of the Agent), insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon an untrue statement or omission or alleged untrue statement or omission
of a material fact contained in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto
or any Permitted Free Writing Prospectus, to the extent, that such untrue statement or alleged untrue statement or omission or alleged
omission was made in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto, or any
Permitted Free Writing Prospectus in reliance upon and in conformity with written information furnished to the Company by Agent expressly
for use in the preparation thereof, it being understood and agreed that the only information furnished by the Agent consists of the information
described as such in <U>Section 5(b)(ii)</U>, by the Company in connection with investigating or defending against any such loss, claim,
damage, liability or action. (ii) The Agent confirms and the Company acknowledges that as of the date hereof no information has been
furnished in writing to the Company by or on behalf of the Agent specifically for inclusion in the Registration Statement, any Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus, other than information about the Agent included in the Prospectus Supplement
under the heading &ldquo;Plan of Distribution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the indemnification provided for in this <U>Section 5</U> is unavailable or insufficient to hold harmless an indemnified party under
subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as
a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company on the one hand and the Agent on the other from the Offering or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Agent on the
other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one hand and the Agent on the other shall be
deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company and
the total compensation received by the Agent, from the sale of Shares on behalf of the Company. The relative fault shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or the Agent and the parties&rsquo; relevant intent, knowledge,
access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Agent agree that it
would not be just and equitable if contributions pursuant to this subsection (c) were to be determined by pro rata allocation or by any
other method of allocation which does not take account of the equitable considerations referred to in the first sentence of this subsection
(c). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence
of this subsection (c) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending against any action or claim which is the subject of this subsection (c). Notwithstanding the provisions
of this subsection (c), the Agent shall not be required to contribute any amount in excess of the amount by which the total price at
which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages that the
Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Neither the termination of this Agreement nor completion of the Offering shall affect these indemnification provisions, which shall remain
operative and in full force and effect. The indemnification provisions shall be binding upon the Company and the Agent and their respective
successors and assigns and shall inure to the benefit of the Indemnified Parties and the Company Indemnified Parties and their respective
successors, assigns, heirs and personal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B><I>Representations and Agreements to Survive Delivery</I></B>. All representations and warranties of the Company herein or in certificates
delivered pursuant hereto, and agreements of the Agent and the Company herein, including but not limited to the agreements of the Agent
and the Company contained in <U>Section 5</U>, shall remain operative and in full force and effect regardless of any investigation made
by or on behalf of the Agent or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons,
and shall survive delivery of, and payment for, the Shares to and by the Agent hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><I>Termination of this Agreement</I></B>. The term of this Agreement shall begin on the date hereof, and shall continue until the
earliest of (i) the sale of Shares having an aggregate offering price of $________ or (ii) twenty four (24) months from the date of this
Agreement or (iii) the mutual termination by both the Agent and the Company upon the provision of fifteen (15) days written notice. Any
such termination by mutual agreement shall in all cases be deemed to provide that <U>Section 3(g)</U>, <U>Section 5</U> and <U>Section
6</U> shall remain in full force and effect. Notwithstanding the foregoing, the Agent shall have the right, in its sole discretion, to
terminate this Agreement if at any time from the date of this Agreement to the effectiveness of the Registration Statement, the Agent
is not fully satisfied, in its sole discretion, with the results of its and its representatives&rsquo; review of the Company and the
Company&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B><I>Default by the Company</I></B>. If the Company shall fail at any Settlement Date to sell and deliver the number of Shares which
it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of the Agent or, except as provided
in <U>Section 3(g)</U>, any non-defaulting party. No action taken pursuant to this <U>Section 8</U> shall relieve the Company from liability,
if any, in respect of such default, and the Company shall (A) hold the Agent harmless against any loss, claim or damage arising from
or as a result of such default by the Company and (B) pay the Agent any commission to which it would otherwise be entitled absent such
default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B><I>Notices</I></B>. Except as otherwise provided herein, all communications under this Agreement shall be in writing and, if to the
Agent, shall be mailed, delivered or telecopied to Maxim Group LLC, 300 Park Avenue, 16<SUP>th</SUP> Floor, New York, New York 10022,
Attention: Clifford A. Teller and James Siegel, with a required copy (which shall not constitute notice) to Ellenoff Grossman &amp; Schole
LLP, counsel for the Agent, at 1345 Avenue of the Americas, New York, New York 10105 Attention: Matt Bernstein, Esq. Notices to the Company
shall be given to it at 2117 SW Highway 484, Ocala FL 34473 Attention: Chief Executive Officer, with required copies (which shall not
constitute notice) to Silverman Shin &amp; Schneider PLLC, 88 Pine Street, 22nd Floor, New York, NY 10005, Attention: Richard Feiner.
Any party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B><I>Persons Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of and be binding upon the parties
hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in <U>Section 5</U>.
Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy
or claim under or in respect of this Agreement or any provision herein contained. The term &ldquo;successors and assigns&rdquo; as herein
used shall not include any purchaser, as such purchaser, of any of the Shares from the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B><I>Absence of Fiduciary Relationship</I></B>. The Company acknowledges and agrees that: (a) the Agent has been retained solely to
act as an sales agent and/or principal in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship
between the Company and the Agent has been created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether the Agent has advised or are advising the Company on other matters; (b) the price and other terms of the Shares set forth
in this Agreement were established by the Company following discussions and arms-length negotiations with the Agent and the Company is
capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated
by this Agreement; (c) it has been advised that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Agent has no obligation to disclose such interest and transactions to the
Company by virtue of any fiduciary, advisory or agency relationship; (d) it has been advised that the Agent is acting, in respect of
the transactions contemplated by this Agreement, solely for the benefit of the Agent, and not on behalf of the Company; and (e) it waives
to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged breach of fiduciary
duty in respect of any of the transactions contemplated by this Agreement and agrees that the Agent shall have no liability (whether
direct or indirect) to the Company in respect of such a fiduciary duty claim on behalf of or in right of the Company, including stockholders,
employees or creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B><I>Governing Law</I></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
including Section 5-1401 of the General Obligations Law of the State of New York, but otherwise without regard to conflict of laws rules
that would apply the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B><I>Counterparts</I></B>. This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart,
the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B><I>Adjustments for Stock Splits</I></B>. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B><I>Entire Agreement; Amendment; Severability; Headings</I></B>. This Agreement (including all schedules and exhibits attached hereto
and transaction notices issued pursuant hereto), together with that certain engagement letter, dated January 9, 2025, entered into between
the Company and the Agent, constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof
may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by
a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is
valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or
unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement. The section
headings used in this Agreement are for convenience only and shall not affect the construction hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B><I>Waiver of Jury Trial</I></B>. Each of the Company and the Agent hereby waives any right it may have to a trial by jury in respect
of any claim based upon or arising out of this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to Follow</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the
Company and the Agent in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
    IMMUNOTECH INC.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    K. Equels</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
    as of the date first above mentioned.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAXIM
    GROUP LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
page to AIM ImmunoTech Inc. Equity Distribution Agreement</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted
Free Writing Prospectus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
Permitted to Authorize Sales of Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
K, Equels</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
Tom.equels@aimimmuno.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Dickey IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
rob.dickey@aimimmono.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of E-mail or Telecopy Confirmation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[COMPANY
LETTERHEAD]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill
Vitale, Head of Equity Trading</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maxim
Group LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300
Park Ave, 16<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RE:
E-mail Confirmation to Sell Stock Utilizing the Equity Distribution Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bill
Vitale and Maxim Equity Trading Team:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Equity Distribution Agreement between AIM ImmunoTech Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;)
and Maxim Group LLC (&ldquo;<B><I>Maxim</I></B>&rdquo;) dated April 1, 2025 (the &ldquo;<B><I>Agreement</I></B>&rdquo;), we hereby
confirm our request by e-mail transmission on behalf of the Company that Maxim is authorized to sell for a period of up to _________
business days, up to ______________ shares of the Company&rsquo;s Common Stock at a minimum market price of $________ per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanks
for all your help and please contact us with any questions,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AIM
    ImmunoTech Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Schedule
D</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individuals
to Which Notice Can Be Given</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
Maxim Group LLC:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
AIM ImmunoTech Inc.:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
K, Equels</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
Tom.equels@aimimmuno.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Dickey IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
rob.dickey@aimimmono.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SILVERMAN
SHIN &amp; SCHNEIDER PLLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wall
Street Plaza </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22nd
Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>88
Pine Street</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, NY 10005</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>212.779.8600</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facsimile:
212.779.8858</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
1, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIM
ImmunoTech Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2117
SW Highway 484</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocala
FL 34473</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Statement on Form S-3</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to AIM ImmunoTech Inc., a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the preparation
of a registration statement on Form S-3 (the &ldquo;Registration Statement&rdquo;), filed by the Company with the Securities and Exchange
Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating
to the offer and sale from time to time by the Company of up to a maximum of $100,000,000 aggregate initial offering price of a presently
indeterminate amount of the following securities (each a &ldquo;Company Security&rdquo; and collectively, or in any combination, the
&ldquo;Company Securities&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
shares of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
shares of the Company&rsquo;s preferred stock, $0.01 par value per share (the &ldquo;Preferred Stock&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
purchase contracts entitling or obligating holders to purchase from or sell to the Company, and for the Company to sell to or purchase
from such holders, a specific or varying number of debt or equity securities issued by the Company or by an entity other than the Company
at a future date or dates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
warrants to purchase Common Stock, Preferred Stock, debt securities, other securities or any combination of those securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
subscription rights to purchase any of the foregoing securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
depositary shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
secured or unsecured debt securities consisting of notes, debentures or other evidences of indebtedness which may be senior debt securities,
senior subordinated debt securities or subordinated debt securities, each of which may be convertible into equity securities; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
units comprised of, or other combinations of, the foregoing securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company Securities may be issued and sold by the Company pursuant to applicable provisions of Rule 415 under the Securities Act, in amounts,
at prices and on terms to be determined in light of market conditions at the time of sale, and as set forth in the Registration Statement,
any amendment thereto, the prospectus contained therein (the &ldquo;Prospectus&rdquo;) and any supplements to the Prospectus (each, a
&ldquo;Prospectus Supplement&rdquo;). The Company Securities may be issued from time to time on a delayed or continuous basis, and this
opinion is limited to the laws, including the rules and regulations, as in effect on the date hereof, which laws are subject to change
with possible retroactive effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we have acted as counsel to the Company in connection with the sale through Maxim Group LLC. as the sales agents from time to time by
the Company of shares of Common Stock (the &ldquo;Sales Agreement Shares&rdquo;) having an aggregate offering price of up to $633,329
pursuant to the Registration Statement, including the Prospectus and the related prospectus for the sale of Sales Agreement Shares (collectively,
the &ldquo;Sales Agreement Prospectus&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
have requested our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering
the opinions set forth below, we have examined such documents and reviewed such questions of law as we have considered necessary and
appropriate for the purposes of our opinion including (i) the Registration Statement, including the exhibits filed therewith, (ii) the
Prospectus, (iii) the Sales Agreement Prospectus, (iv) the Company&rsquo;s amended and restated certificate of incorporation as amended
(the &ldquo;Certificate of Incorporation&rdquo;), (iv) the Company&rsquo;s restated and amended bylaws (the &ldquo;Bylaws&rdquo;), (v)
the corporate resolutions and other actions of the Company that authorize and provide for the filing of the Registration Statement, and
we have made such other investigation as we have deemed appropriate. We have not independently established any of the facts so relied
on.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this opinion letter, we have assumed the accuracy and completeness of each document submitted to us, the genuineness of all
signatures on original documents, the authenticity of all documents submitted to us as originals, the conformity to original documents
of all documents submitted to us as facsimile, electronic, certified, conformed or photostatic copies thereof, and the due execution
and delivery of all documents where due execution and delivery are prerequisites to the effectiveness thereof. We have further assumed
the legal capacity of natural persons, that persons identified to us as officers of the Company are actually serving in such capacity,
that the representations of officers and employees of the Company are correct as to questions of fact, that the board of directors will
have taken all action necessary to set the issuance price of the Company Securities to be offered and sold and that each party to the
documents we have examined or relied on (other than the Company) has the power, corporate or other, to enter into and perform all obligations
thereunder and also have assumed the due authorization by all requisite action, corporate or other, the execution and delivery by such
parties of such documents, and the validity and binding effect thereof on such parties. We have not independently verified any of these
assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions expressed in this opinion letter are limited to (i) the General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;)
and the applicable statutory provisions of the Delaware Constitution and the reported judicial decisions interpreting such statute and
provisions and, solely in connection with the opinions given in numbered paragraphs 1, 2, and 9 below and (ii) the laws of the State
of New York solely in connection with the other opinions given below. We are not opining on, and we assume no responsibility for, the
applicability to or effect on any of the matters covered herein of (a) any other laws; (b) the laws of any other jurisdiction; or (c)
the laws of any county, municipality or other political subdivision or local governmental agency or authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and in reliance thereon, and subject to the assumptions, qualifications, limitations and exceptions set forth below,
we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
With respect to shares of Common Stock, when (a) the board of directors of the Company has taken all necessary corporate action to approve
the issuance and terms of the offering thereof and related matters, including without limitation the due reservation of any Common Stock
for issuance, and (b) certificates representing the shares of Common Stock have been duly executed, countersigned, registered and delivered,
in each case in accordance with the Certificate of Incorporation and Bylaws, either (i) in accordance with the applicable definitive
purchase, underwriting or similar agreement approved by the board of directors of the Company upon payment of the consideration therefor
(which consideration shall not be less than the par value of the Common Stock) provided for in such definitive purchase, underwriting
or similar agreement, as applicable, or (ii) upon conversion, exchange or exercise of any other Company Security in accordance with the
terms of such Company Security or the instrument governing such Company Security providing for the conversion, exchange or exercise as
approved by the board of directors of the Company, for the consideration therefor set forth in the applicable agreement and approved
by the board of directors of the Company, which consideration shall not be less than the par value of the Common Stock, such shares of
Common Stock will be validly issued, fully paid, and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
With respect to shares of any series of Preferred Stock, when (a) the board of directors of the Company has taken all necessary corporate
action to approve the issuance and terms of the shares of such series, the terms of the offering thereof and related matters, including
the adoption of a certificate of designation or amendment to the Certificate of Incorporation fixing and determining the terms of such
Preferred Stock conforming to the DGCL, the filing of a certificate or amendment, as applicable, with the Secretary of State of Delaware,
the payment in full of any filing fees attendant thereto, and the due reservation of any Common Stock and Preferred Stock for issuance,
and (b) certificates representing the shares of such series of Preferred Stock have been duly executed, countersigned, registered and
delivered, in each case in accordance with the Certificate of Incorporation and Bylaws, either (i) in accordance with the applicable
definitive purchase, underwriting or similar agreement approved by the board of directors of the Company upon payment of the consideration
therefor (which consideration shall not be less than the par value of the Preferred Stock) provided for in such definitive purchase,
underwriting or similar agreement, as applicable, or (ii) upon conversion, exchange or exercise of any other Company Security in accordance
with the terms of such Company Security or the instrument governing such Company Security providing for the conversion, exchange or exercise
as approved by the board of directors of the Company, for the consideration therefor set forth in the applicable agreement and approved
by the board of directors of the Company, which consideration shall not be less than the par value of the Preferred Stock, the shares
of such series of Preferred Stock will be validly issued, fully paid, and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
With respect to the issuance of any purchase contracts, when (a) the board of directors of the Company has taken all necessary corporate
action to approve the purchase contract agreement to be entered into in connection with the issuance of any purchase contracts and such
purchase contract agreement has been validly executed and delivered by the purchase contract agent and Company, (b) the board of directors
of the Company has taken all necessary corporate action to approve the specific issuance and terms of any purchase contracts duly established
in accordance with the applicable purchase contract agreement and (c) such purchase contracts have been duly executed, countersigned,
registered, issued and delivered in accordance with the purchase contract agreement and the applicable definitive purchase, underwriting
or similar agreement, as applicable, for the consideration therefor set forth in the applicable agreement and approved by the board of
directors of the Company, such purchase contracts will constitute valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors&rsquo; rights
generally, concepts of reasonableness and equitable principles of general applicability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
With respect to the issuance of any warrants, when (a) the board of directors of the Company has taken all necessary corporate action
to approve the warrant agreement to be entered into in connection with the issuance of any warrants and such warrant agreement has been
validly executed and delivered by the warrant agent and Company, (b) the board of directors of the Company has taken all necessary corporate
action to approve the specific issuance and terms of any warrants duly established in accordance with the applicable warrant agreement
and (c) such warrants have been duly executed, countersigned, registered, issued and delivered in accordance with the warrant agreement
and the applicable definitive purchase, underwriting or similar agreement, as applicable, for the consideration therefor set forth in
the applicable agreement and approved by the board of directors of the Company (assuming the securities issuable upon exercise of the
warrants have been duly authorized and reserved for issuance by all necessary corporate action and in accordance with applicable law),
such warrants will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their
terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors&rsquo; rights generally, concepts of reasonableness
and equitable principles of general applicability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
With respect to the subscription rights, when (a) the board of directors of the Company has taken all necessary corporate action to authorize
the issuance and the specific terms of such subscription rights, the terms of the offering thereof, and related matters and (b) such
subscription rights and agreements relating to the subscription rights have been duly executed and delivered in accordance with the terms
thereof, then such subscription rights will be valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
With respect to the depositary shares, when (i) the board of directors of the Company has taken all necessary corporate action to approve
the issuance and terms of the depositary shares, the terms of the offering thereof and related matters, including the adoption of a certificate
of designation relating to the preferred stock underlying the depositary shares as required by applicable law and the filing of the certificate
of designation with the Secretary of State of the State of Delaware as required by applicable law; (ii) the depositary agreement or agreements
relating to the depositary shares and the related depositary receipts have been duly authorized and validly executed and delivered by
the board of directors of the Company and the depositary appointed by the Company; (iii) the shares of preferred stock underlying the
depositary shares have been duly authorized, validly issued and deposited with the depositary under the applicable depositary agreement;
and (iv) the depositary receipts representing the depositary shares have been duly executed, countersigned, registered and delivered
in accordance with the appropriate depositary agreement approved by the Company, upon payment of the consideration therefor provided
for in the applicable definitive purchase, underwriting or similar agreement, the depositary shares will be legally issued and will entitle
their holders to the rights specified in the deposit agreement and the depositary receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
With respect to any debt securities, when (a) the board of directors of the Company has taken all necessary corporate action to approve
an applicable indenture, if any, or any amendment or supplement thereto or other agreement in respect thereof, if any, and such indenture,
if any, or any amendment or supplement thereto or other agreement in respect thereof, if any, has been validly executed and delivered
by the Company, (b) any applicable indenture, if required, has been duly qualified under the Trust Indenture Act of 1939, as amended,
if qualification is required thereunder, (c) the board of directors of the Company has taken all necessary corporate action to approve
the specific issuance and terms of any series of debt security duly established in accordance with the applicable indenture, if any,
and (d) such debt security have been duly executed, countersigned, registered, issued and delivered either (i) in accordance with the
indenture, if any, or any amendment or supplement thereto or other agreement in respect thereof, if any, the applicable definitive purchase,
underwriting or similar agreement, as applicable, or (ii) upon conversion, exchange or exercise of any other Company Security in accordance
with the terms of such Company Security or the instrument governing such Company Security providing for the conversion, exchange or exercise
as approved by the board of directors of the Company, for the consideration therefor set forth in the applicable agreement and approved
by the board of directors of the Company, such debt securities will constitute valid and binding obligations of the Company, enforceable
against the Company in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors&rsquo;
rights generally, concepts of reasonableness and equitable principles of general applicability, provided that we express no opinion as
to (x) the enforceability of any waiver of rights under any usury or state law, (y) the validity, legally binding effect or enforceability
of any provision of the indenture that requires or relates to adjustments to the conversion rate at a rate or in an amount that a court
would determine in the circumstances under applicable law to be commercially unreasonable or a penalty or forfeiture or (z) the validity,
legally binding effect or enforceability of any provision that permits holders to collect any portion of stated principle amount upon
acceleration of the debt securities to the extent determined to constitute unearned interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
With respect to the issuance of any units, when (a) the board of directors of the Company has taken all necessary corporate action to
approve the unit agreement, if any, to be entered into in connection with the issuance of any units and such unit agreement, if any,
has been validly executed and delivered by the unit agent, if any, and Company, (b) the board of directors of the Company has taken all
necessary corporate action to approve the specific issuance and terms of any units duly established in accordance with the applicable
unit agreement, if any, and (c) such units have been duly executed, countersigned, registered, issued and delivered in accordance with
the unit agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, as applicable, for the consideration
therefor set forth in the applicable agreement and approved by the board of directors of the Company, such units will constitute valid
and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to applicable bankruptcy,
insolvency and similar laws affecting creditors&rsquo; rights generally, concepts of reasonableness and equitable principles of general
applicability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
With respect to the Sales Agreement Shares which are a portion of the Common Stock being registered, when the Sales Agreement Shares
have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers thereof,
and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Sales
Agreement Prospectus, the issuance and sale of the Sales Agreement Shares will be duly authorized, validly issued, fully paid and nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions set forth above are subject to the following additional assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the Registration Statement, any amendments thereto (including post-effective amendments), will have been declared effective under the
Securities Act and such effectiveness shall not have been terminated, suspended or rescinded;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
all Company Securities will be issued and sold in compliance with applicable federal and state securities laws, rules and regulations
and solely in the manner provided in the Registration Statement and the appropriate Prospectus Supplement and there will not have occurred
any change in law or fact affecting the validity of any of the opinions rendered herein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
a definitive purchase, underwriting or similar agreement and any other necessary agreements with respect to any Company Securities offered
or issued will have been duly authorized and duly executed and delivered by the Company and the other parties thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
the final terms of any of the Company Securities (including any Company Securities comprising the same or subject thereto), and when
issued, the issuance, sale and delivery thereof by the Company, and the incurrence and performance of the Company&rsquo;s obligations
thereunder or respect thereof in accordance with the terms thereof, and any consideration received by the Company for any such issuance,
sale and delivery, will comply with, and will not violate, the Certificate of Incorporation or Bylaws or any applicable law, rule or
regulation, or result in a default under or breach of any agreement or instrument binding upon the Company and will comply with any requirement
or restriction imposed by any court or governmental body having jurisdiction over the Company or to which the issuance, sale and delivery
of such Company Securities or the incurrence and performance of such obligations may be subject or violate any applicable public policy,
or be subject to any defense in law or equity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
the Company shall have taken any action required to be taken by the Company, based on the type of Company Security being offered, to
authorize the offer and issuance thereof, and such authorization shall remain in effect and unchanged at all times during which the Company
Securities are offered and issued and shall not have been modified or rescinded (subject to the further assumption that the sale of any
Company Security takes place in accordance with such authorization), the board of directors of the Company shall have duly established
the terms of such Company Security and duly authorized and taken any other necessary corporate action to approve the issuance and sale
of such Company Security in conformity with the Certificate of Incorporation and Bylaws (subject to the further assumption that neither
the Certificate of Incorporation nor Bylaws have been amended from the date hereof in a manner that would affect the validity of any
of the opinions rendered herein), and such authorization shall remain in effect and unchanged at all times during which the Company Securities
are offered and issued and shall not have been modified or rescinded (subject to the further assumption that the sale of any Company
Security takes place in accordance with such authorization);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
there will exist, under the Certificate of Incorporation, the requisite number of authorized but unissued shares of Common Stock or Preferred
Stock (and securities of any class into which any of the Preferred Stock may be convertible), as the case may be; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
to the extent they purport to relate to liabilities resulting from or based upon gross negligence, recklessness or other conduct committed
or omitted willfully or in bad faith or any violation of federal or state securities or blue sky laws, we express no opinions concerning
the enforceability of indemnification provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinions above are subject to the effects of (i) bankruptcy, insolvency, fraudulent conveyance, fraudulent transfer, reorganization,
receivership, moratorium and other similar laws relating to or affecting enforcement of creditors&rsquo; rights or remedies generally,
(ii) general principles of equity, whether such principles are considered in a proceeding of law or at equity, and (iii) an implied covenant
of good faith, reasonableness and fair dealing and standards of materiality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is limited to the Delaware General Corporation Law, including the statutory provisions of the Delaware General Corporation Law
and all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws. We hereby consent
to the filing of this opinion as an exhibit to the Registration Statement and to the use of our name under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus. In giving our consent, we do not thereby admit that we are experts with respect to any part of the Registration Statement,
the Prospectus, the Sales Agreement Prospectus or any Prospectus Supplement within the meaning of the term &ldquo;expert,&rdquo; as used
in Section 11 of the Securities Act or the rules and regulations promulgated thereunder by the Commission, nor do we admit that we are
in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
truly,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Silverman Shin &amp; Schneider PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Silverman
Shin &amp; Schneider PLLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>aim-20250401.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayGabP9z5Z8CekhvWBybWl6Xy0uvt0bmy38JZwGgXgJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:AIM="http://aimimmuno.com/20250401" elementFormDefault="qualified" targetNamespace="http://aimimmuno.com/20250401">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aimimmuno.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20250401_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aim-20250401_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>aim-20250401_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>aim-20250401_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aimimmuno.com/role/Cover" xlink:href="aim-20250401.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aimimmuno.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  01,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-27072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AIM
IMMUNOTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000946644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-0845822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2117
    SW Highway 484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ocala<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">448-7797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AIM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,13A%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,13A%I']M,![P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/;
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ Q%.$6F60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( ,13A%I']M,![P   "L"   1              "
M <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,13A%J97)PC$ 8
M )PG   3              "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ Q%.$6B61S;-1!   @A   !@              ("!(@@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,13A%J?H!OPL0(
M .(,   -              "  :D,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimimmuno.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aim-20250401.xsd</File>
    <File>aim-20250401_lab.xml</File>
    <File>aim-20250401_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "AIM",
   "nsuri": "http://aimimmuno.com/20250401",
   "dts": {
    "schema": {
     "local": [
      "aim-20250401.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aim-20250401_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aim-20250401_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://aimimmuno.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-01",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aimimmuno.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001641172-25-002702-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-002702-xbrl.zip
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M/6X5!='[7<Y,$DHM:HH=8['@-(F2+&'K7^3)ITBPK54VD2L@8(.:AK8B"!1
M6R8'!R'22L<0W FB("2R(_*7 %5B(7'[\&"=[;O$KJ#H-ZSA@)5!0-)KSX1%
M!HRC6@0J0E >XQ>;>9INB7@3/)803PB!Y@&06OH0<8),]D)5!/ID:T&BK9P?
M]\?3U3+)J.WDLBUQ-B<!YJH9R2@/@@W E,E"7H;X SJ>_F7U5Z2C''?_#5\*
MK)+'+O:;%:= ]BFKRA4$'18U!Q9)$"C ODP:;C@JI:C0^LA.U3!K:8Y1[@H
MJRW=]8W"(#K=YJCUY6_TM:<A_W(7/4I3!'@AP2YS/?3;3)K#?UT3! (=QEHG
M):44::V/%Q(.4]:Z?Q&P]K8(6/<L M8A+@+60Q<!:V^+ +W;(D6(')=N5S19
M8R Y8:?:-10=EDT^+-*@4(']@6-&%8(.,:XS6N8ISE1Z?K')]W\E/UA:">B<
MY;3LLEDEM;2)@F"DRUDKK661=*XF1DKMFHMMG&0D+LQ<)0RS*,&T2H]HNR+>
M'^*,EH'F*W!Z]&$P-,QD"Z<B3.<RK (/J2Y=7THO'L#XE5#Z,^.O;$%PRAF)
MBVLIMCM%W7JW3\STV&X^- .(@\!IB$/@T1D5-'Y244B'E5?"O)#TC=,MR[#(
MWR47MI$)T+DE![#9),80!42*W1E 2"5&A=K/"]I%]HAJD57\[A#80$CN^'7M
M3M/&6]M6;4#,=!J$WN$N<WX<UL9%E*=7+#.B?B\B>2%?<(9+;V![(;GKERJ[
M3)MO4]JT 2'4:1!\?[**4:EBL&;*6\H8,9-+K37O>$K<4+E/'-.RV,X=4TD"
MPL/FJR.#C$!:ZX6%Q093^GF;)HRD\$1DJ-RR8+789*$A"8@%FR^ A5R*M-8+
M"Y<;(M9R>OM)\-?LL<S/"K8-4+MEH]-RDQ&K-"!6NOP!S.@05,3HE+I^X-D=
M$HH761;AEEJDCK$!S1K,M'0A 0.9:]%"2:2NM]SP#"TY^IH2E#T2=%G^#%T]
M$WQ1CZ]?&HDB]4)$L2IG,18VA+K$SG]U!#3<^NV1EC((D'KMP;]#4D4@'>*8
MFEO)L*B?Q^4FYAG9@&\[](>X(FBH><U1GSX(F@::-)G*PYHGUWD@4I$^LQG5
MD]O#2[R&R/'*V&+06!C7%$$P MJ"EL7UWPKPDSMONZ))=$4YAJ^R-#2.,^:U
M[1G)\@Z"@ AHNX)2Y.5"E"N]]/]GS)[$]CF+]G>"1X2HIZS2:K3JN_XV,-HM
M,V]J4I.F0:$!<?86OP"!ARI0K8X/M1G+Y\4\]="XRN;&HZ?%(Y8'\':;I6H&
ME<;@J^"=08YO+PQH@'&3H2,B(/0&V(1N..21* _]@(I@5(OV='Z6'K( DOCS
M_IX\$*'>.UB27?99[NBIXPQC0*SKL[?!S3%/YGH#@X#PK6ZA4[T4U2M *_6,
M6%D%^DU5@O):;+]?7M]T+3_)S7J3_&N%4R*W_!=02P,$%     @ Q%.$6F#4
M+<';!P  \5X  !0   !A:6TM,C R-3 T,#%?<')E+GAM;.6<77/B-A2&[SO3
M_^#2:T(@V;;))MTA).PPF]W0D-UM>[,C; &:R!(CV0'^?24;"!^6?-)A?3)M
M+A)BCJ3S/L>6?:R/BW?SF =/5&DFQ66M>71<"Z@(9<3$^++V>5!O#SJ]7BW0
M"1$1X5+0RYJ0M7>___A#8'XN?JK7@RZC/#H/KF58[XF1?!M\(C$]#]Y3015)
MI'H;?"$\M4=DEW&J@HZ,IYPFU'R1-WP>O#EJO1D&]3J@WB]41%)]ON^MZYTD
MR52?-QJSV>Q(R"<RD^I1'X4RAE4X2$B2ZG5MQ_/CY4]>_((S\7AN?PV)IH'A
M)?3Y7+/+FFUWV>SLY$BJ<:-U?-QL_/GQ=A!.:$SJ3%AN(:VM2ME:BLHUS\[.
M&MFW*],]R_E0\54;)XV5.^N:S;?,8[_AB6;G.G/O5H8DR<)>VDS@M+#_U5=F
M=7NHWFS53YI'<QW55O S@DIR>D]'@?UKHK=NE;"8Q7$JI(U8PW[;Z$AS1AI7
MLW(314>7-6-E:F^].3X]SNK^><LF64S-B:F9/:]J00/4;J9#T_!H+)\:-(SR
MIOM/TVNF0RYUJNBV"ZO3;*^@\>O4?K .GF;.%=9R."=OE++7T $<==9T.&?;
M,Z*B!Q-D,3Z P][:#N=T3V@64?6@B.T)VTH1,:8Q%8G^UYZ75_F]W.]+SD)&
M=5_)\$#N%U7I<W^JJ#92L_[FUAS8*D+GB>G3:;2JR$H =P\)2ZSULLMN!G7;
MOZ>6J_F86RX]6?G"9;C5/+?]H%0 ,A%E.1GSX9F,^>=;UE![J!-%PF15$R=#
MRK/ZOQF;'9-&!5ZM2#R8&HN=VK;8]6DS:FT5!E*9,\"P7M5%5+@5J_W;P]*B
M,27*5%0/)XROPSQ2,G;169*0#D<W09DFJJ'9-NU'UH<N)^-BG#LF0)Y-#*"%
M:K"(7E,=*C:U7$K ;ED"^;90^19HJQCSZMJYIV-F_;6NV(?>[.[C[Q<<18#@
M3S!["J]:I BTA4@)OZ=3J4K ;UL">9]B\B[2AH3YCY2HA"J^@)#>,P;"?H,)
MVZ$0B;=Y*#1/AY8/!/B^-9#X+Z@/'@Z-2,@'$\JY3=V( )WE1?9 [+]B8G?K
M? 7@;Y[L_=W<6N#L-XH \?_V6O#OJ46*0)\J)B-S2U< ]GO&0.IGF-0="E%Y
MWX@(2GMM"LY_\&'OR$-"W64Z)#SWJ&N.:3_N G,H<I2<LU0F*O:_*%%@Z!O&
M4.0H:6B)Q(J!=U*EMISQ]BIN:RARE 2T3&3%S&]$PI*%'7G[E,;#YQ>GVZSW
MK:",49).ER@4MJLW#2*Q XH^OKN64,8HN:9/' KGCM&C".^)B,X_T(4/])XI
ME#1*CNF5AX*ZKUA,U&+ PO).8]\6"ALEL_0+1*']0.:]R*AB(Y8/R9=#=Q:!
MLD=)*T%R44+0$Z%44[GQNK@C4W,]+CHR\G;I)06AX4#)-U\@'24H[2@RN/3R
MSRT3M.D+1:$Y>(P(+P >F:\$>^MEV%MP["AY:*G,5X+]Y&783^#847+14IF8
MV#OFXYUZD#/'"+33&(H<)1<MD8@)/+O3W*F^DD\LGYE81GVO!!0]8HKJ%XMZ
MPN<W><C9OK*$\D9,5XO%87+N2YT0_C>;ECU)%MM#F2,FKCZA5;]@S.-N7UJX
MIA+MF$#YHN2JA7*J1FHCK"AQG[[;%E"@* EHD9B*>=Y*._8QD<+[/G;?"LH5
M)9-TB:JZX[4SB;7STM_X&CR##:5;W951,<:OBB7&@XZT$Z^7[V@<HV(.4RA>
ME/3/*Z]BU(-L(GW"Q/BC>4)4C/!BSD5V4,@HR9Y;6,6$^XK:2%/SV)W-X[)+
M#=3=:.3J>7WV4.(HN5ZY4%SR/:U3JE[*OZ 4- HH:1]4=-7]# U3T^TMFJWA
M@UTQX^AE]JR@K%%2/I>HBME^DLM548-%/)3<O3RDT!!*&"7!\TBK&/*6'\5X
M=TR@8%$RNT(Y2'W"S3R<V,6([MD+Q990P"B9GD\<6M\[!O6]XQ?VO2@9GTL4
M$MM\;KBYHNZ&G(V)>R69MP!XG0TF<8_4JM?O94M^[%X**L[\Z)H/Q=@=IE#@
M.$LD??*J1IU&+*%1[E*7"2)"DU*MU[4YLO/R4M  X*RA!(I&>;W_E7+^0<B9
M&%"BI:!1_JCO>\/O+ *- N(88HE<E!!\D3PUE%0V$50YK@&'*10YXMBA0Q[.
MW,M\4O/ZWI-OFN,C[BH!!8\XB.@7BS0_+:'69_9$KTE"EA[Z^+M*0/DC#BCZ
MQ:+-GU<=<^,92_^8^8XAE#;B5-A":2B0!S'A_"K53%#M[5MV#*&0$>>\%DI#
M@7P34S4VG=I[)6?)9+FVTP?;40 *'7%FJU<J#OSY\SKR?/V;EWR!-7AW D3L
M3I%8VVZ$H9U(D=_)1424@[K/'LH==6&E6VC%Y.^2"56;ST^9,SV3M_DF/927
M@D8!)5V%BL:YMVZLY/?>6K?LH+P1$],B83AKIM(A9V&72^)]+M\R@_)%S$(+
M9*'@O2+B4:73)%S830<IM<,G>GVU 1(B8 70D"#FIR]"@?.Z0,:Q74PDP\?!
MQ(C6=VF2[2%L_/.^-/"6@X8&<Q$G0#C24Y!^7NA%HZO%/1U19:<I/-!Y<F4:
M>O0_% &*0^.#NJ,0&$-!F"X:>[INS8$#;74*VI'X4/NJ_M\:*]CI^/LVZ-BI
M^#_8J&]G8]R6E]>K_67W)S='_@%02P,$%     @ Q%.$6H#6/= 0G@  V0,$
M  D   !E>#$M,2YH=&WLO7N/VU:6+_J_ 'T'WD9/0P70E2H[3B=Q3H#R(QEC
M\O#8SNG3]^)B0$E4%6.)5)-4E=6?_J[GWFN3FY+*KCRN2P<XTW%)(O=S/7_K
MM[[YS[<__O#M>/3-?[ZX> [_F^#_^^;MR[<_O/CVF\_X?^'3S^3C;Y[^_/R?
MR9NW__SAQ?_ZRZ(JVZ^3\[-UF[PM5GF3_)3?)*^K55:F_(<T>9/7Q>(O\$/X
MZ:O;_NY)LLKJRZ)\T%;KKQ/XNOO#M&K;:A7^;9DOX*EG3Y(V?]\^R);%9?EU
M,LO+-J__\NW?RFFS?O+-9Z_^N*'4Q>55^Y=OOWGZ[8OW5\6T:,>C\]/S;SY[
M^NT?.JP_T0KI4+[Y[N>?WMKW/UADJV*Y_7K?".B[3?'OG =,BWWQ\L?QZ.5J
MM2FKM_GL*GE9SDYYT?$M?XZUO],)_[(>C]HJ^>NC].SL#/]_\N8JJ^$IU2)Y
M5JU659F\::O9NT]Z$;[YY=L7_]H4[78\>EXT;5U,-VT!,[^XK/-\!6_\YK-?
MOOVSK(!(AC_!#509=6=;<;&NBR4(NC1Y>/;P\7&Q[4A^W31ML=C>Y7+_F+TO
M5N/1]W6U62<__/#LS[#@O\$T'X%0>Y75[Y*+Z[S<Y&ER_L4W;WYY]6U[]<UG
M^+_)=\NJJC_1R<,WQZ-_5O6[E'Z$_P6?G#U\^(G.5V_J)SFY'[)Y 3_(RGGR
M/6BE)>JFKS_1N?[I-E+^6)3S'%]]=OJX*.]4^45,SS3)DN?Y,KL!DRR95?6Z
MJC.R3";M59[\;3G_UZ9Z@@;,RV_!6%MGY?:;SUZ2I?*WFCX[29-U7:VK!H8"
M9E[1-)N<SD^3+Y=)>P6B__(J(460.#TP'O4??W%)9E#WX5F3--D2SR1^GB:-
M,QYG;#PV:#S"(+(ZN<Z6\/*_GIV>G9TGZ[SF+R>3[C2,S=EYW7@$#\:AR60C
MR\#6:_>7R55V7927,',8*!AUEUF;PR 7L!7P5[ Z9OC/!*8?VL(P$K V5S#)
MO(4=J]NK\>@JK_.B/$W>PJO%5IY590-V8P)+4-3Y<HO/RC;M557#_LX3L":3
M34EK/S<K9*>*[YWFB7R'-JA:PB^W=KJG]^@VW+OK#\=I/-)SC6<,]A[.U:+
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MIB2]RKQI:'_6FYJ=>'C$&_P,AG!^'A>[LM;PGD:^F<'"%GS)S0Y[.3 Y!U6
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M9DC%0#:7J\#QR!<ZN@[WO?\:*!^$64HP3C O!?CZN<U68Y@>8P&$S-$H'2&
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M]"\(YDX!&$3_8!0'GD8-T9 "8[FL;@C"NMP25H"QL;X'A'/;_!$)R9+Q8,%
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M-)J<"LCR7;C$[]6F01]N8Y"^11$T" #6ZA)ZQ5JJ.%JAHQ,"^UQD?U$:/2"
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MUL %"^"OGLZ6S"B$1,[R9>[!OUBUWU!VZEHQ<W7P9^>$BZTED4GC^Q+!P:P
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MIB<%14NHC4S);60D9L+4AVQQLNAQ]2 NC:GAE8DOC^X4>]N^&MR_V83+*(@
MKRW0=>5/3U+;1]OWXDB=18C1#5,25%MRY<%:H<&F(2V8KJB*,3Y^<U6AU%/"
M-FPJ\[[5ZIX_RD3\\US,/1B\AT<,WEUB\!X>,7B?, ;OC]$^^6[M0]"(7H_<
M?>".K@J:F&K!)0CW#9R2$ZM\"!@3!.W)NNT2J#42XG-%!]U.[15#_[*5AWK9
MO+=GD6Z:S6KMTP!D:[G7(5U!]'T\8C)QR=HT45;^(NP=LX>B?G!Y*%7:8G'"
MV":BE$6U<XJ:F48X)Y0193&%(C>X]0ZN92HDO=Z*,;ESWJEHF ]!?<F!G_-
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M@:,!&E?50->YG*M ,KT)(Z%1T+P2&^V%<.0B2QV,2VM*HJGQ6,B@XY'6BI,
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MT?YIRP!;W&V)R,;_WQ\.NST*;>:F,>-1S<TU!II4]UM34);)V!DN8 CN;/X
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MO\)?FWDQDY9Y31_4Z_*]C?:ZD]"_1*)X (6V.L=&%Q)#JI)E12!P8[,K2B5
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M"1=POM#5?\W#ZO>;[V09KS+N4+3-6XF"PB,O^(VO<S!;6NKL[4J@F-KHOW6
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M:9%KNJ*6;.;6><RJ<.%+'V>#K8J%?F VJ^FF;G(+,@SP$0L!*X+(!ZLN#>@
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M?$=Y\ E/>+*,Q8'Q]E.>A<[#LJ KUVX=:=4"QU.[U##\=5I7[\Q?%CF'%O#
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M+/U$[)6!L@HGLR3(THSN#W.(X3%2U/32J\32DQ'*1!<K 8B=@G=J8Q4:V"1
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MT#X.*/]T;T_^J>74U #0PAY2!*!!\=\278_\SG*$7,X&^U'(+.OS%UE(BL>
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MR2U&<U0?OGWV[L4O$$O^]J?+-Z__]/]02P,$%     @ Q%.$6GX&6XA7'
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MD&7%08JRSEB@YJE A,U:N0M\S(WX'+XL=5DSEQ&VX"#!6O\&SR+$<OE(A68
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M3)3ILFIK/B7L4+V%"X T6YW1#.3A^IXL:9]Y.^$..[A3'RH_LSZXI1E3X+G
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M%5/*KM2D$5BG]<S#DU7 WAPD9,WY-9BAEO8G.1"9>&/?]R['>NA?CL78:!R
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M=NUM[NVME5,8R76$/L:??7=@5/\?4$L! A0#%     @ Q%.$6N+E80\I P
MXPL  !               ( !     &%I;2TR,#(U,#0P,2YX<V102P$"% ,4
M    " #$4X1:(<O)9OX*  " A@  %               @ %7 P  86EM+3(P
M,C4P-# Q7VQA8BYX;6Q02P$"% ,4    " #$4X1:8-0MP=L'  #Q7@  %
M            @ &'#@  86EM+3(P,C4P-# Q7W!R92YX;6Q02P$"% ,4
M" #$4X1:@-8]T!">  #9 P0 "0              @ &4%@  97@Q+3$N:'1M
M4$L! A0#%     @ Q%.$6GX&6XA7'   .\D   D              ( !R[0
M &5X-2TQ+FAT;5!+ 0(4 Q0    ( ,13A%J=ZHIQJ!D  $+"   +
L      "  4G1  !F;W)M."UK+FAT;5!+!08     !@ & &D!   :ZP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aim-20250401.xsd" xlink:type="simple"/>
    <context id="AsOf2025-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000946644</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-04-01" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-04-01" id="Fact000004">0000946644</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-04-01" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-04-01" id="Fact000010">2025-04-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-04-01" id="Fact000011">AIM IMMUNOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-04-01" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-04-01" id="Fact000013">001-27072</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-04-01" id="Fact000014">52-0845822</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-04-01" id="Fact000015">2117     SW Highway 484</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-04-01" id="Fact000016">Ocala</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-04-01" id="Fact000017">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-04-01" id="Fact000018">34473</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-04-01" id="Fact000019">352</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-04-01" id="Fact000020">448-7797</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-04-01" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-04-01" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-04-01" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-04-01" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-04-01" id="Fact000025">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="AsOf2025-04-01" id="Fact000026">Common     Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-04-01" id="Fact000027">AIM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-04-01" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
